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Resumo 
A administração de fármacos por via pulmonar tem sido abordada com elevado interesse, 
conduzindo-se ao crescimento do desenvolvimento de sistemas de libertação específicos 
para esta via. A sua reduzida atividade enzimática, a prevenção do metabolismo hepático, a 
superfície elevada, o fino e permeável epitélio alveolar e a vasta rede vascular, tornam-na 
elegível para a administração sistémica. Mas também, por permitir a elevada deposição de 
fármaco em elevada concentração numa zona específica do pulmão, permitindo assim, 
aumentar a sua ação terapêutica, reduzindo a dose total, efeitos adversos sistémicos e 
efeito de primeira passagem. É largamente utilizada para a veiculação de fármacos para o 
tratamento local de doenças respiratórias como a asma e fibrose cística, e atualmente 
investigada para a veiculação de antibióticos para o tratamento de doenças infeciosas, como 
a pneumonia ou a tuberculose.   
A tuberculose apresenta ainda uma elevada prevalência e incidência a nível mundial, em 
2012, estimou-se o aparecimento de 8.6 milhões de novos casos e 1.3 milhões de casos de 
mortalidade. Sendo que uma das principais causas de morte é a baixa adesão a terapia oral 
atual, e consequentemente a falha terapêutica desta. A administração de sistemas que 
veiculem fármacos antituberculosos tem sido vista como uma abordagem terapêutica que 
potencialmente será eficaz e segura. Os sistemas micropartículados produzidos, por 
exemplo, por atomização, tem sido bastantes explorados, devido, a se poderem modular as 
suas características, de modo, a que exibam características aerodinâmicas adequadas 
(tamanho geométrico, densidade e forma) para alcançar a região alveolar.  
A goma de alfarroba (LBG) é um polissacarídeo neutro, que é extraído a partir das sementes 
de alfarroba, e tem sido largamente utilizado, em aplicações farmacêuticas, devido, a sua 
baixa citotoxicidade, propriedade bioadesivas e gelificantes. Este polímero pertence a classe 
dos galactomanamos, e é composto por unidades de mannose e galactose, num ratio 
aproximadamente de 4/1. A sua estrutura molecular consiste numa ligação linear de 
unidades (1-4)--mannose com uma unidade de (1-6)-α-galactose. A obtenção de 
micropartículas com esta estrutura, e com capacidade de atingirem a região alveolar, 
permite proporcionar o direcionamento destes sistemas para os macrófagos alveolares, 
onde reside o agente infecioso, Mycobacterium tuberculosis, e permitirem que haja a 
libertação intracelular dos fármacos veiculados. Este direcionamento deve-se ao facto de os 
macrófagos alveolares infetados expressarem o receptor da mannose, que ao reconhecer 
estruturas com mannose, irá conduzir a sua fagocitose, de um modo, mais específico e 
rápido, comparativamente com sistemas que não tenham esta estrutura.  
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Neste contexto, este trabalho propõe o desenvolvimento de sistemas microparticulados, 
utilizando a goma de alfarroba, para a produção de micropartículas através da técnica de 
atomização. Pretende-se que este polímero veicule dois fármacos antituberculosos de 
primeira linha, a isoniazida (INH) e a rifabutina (RFB). Os sistemas microparticulados obtidos 
serão caracterizados em termos de propriedades aerodinâmicas, de eficácia de 
encapsulação e capacidade de permitirem a libertação dos fármacos num ambiente alveolar 
e do fagolisossoma. A sua biocompatibilidade será analisada em duas linhas celulares 
representativas do epitélio alveolar (A549) e dos macrófagos alveolares (macrófagos 
diferenciados a partir de THP-1). A capacidade de as partículas com uma matriz de LBG em 
serem fagocitadas será avaliada na dose de 50 µg/cm2 em duas linhas celulares de 
macrófagos, macrófagos diferenciados a partir de THP-1 e em macrófagos alveolares 
provenientes de ratinho (NR8383). A capacidade destas micropartículas em ativarem 
macrófagos será também avaliada nos macrófagos diferenciados a partir de THP-1.  
A utilização da goma de alfarroba neste contexto nunca fora descrita anteriormente. Pelo 
que torna as quatro formulações desenvolvidas com diferentes ratios de fármacos, uma 
nova abordagem/proposta para a terapêutica de tuberculose, ou a sua potencial adaptação 
para outra doença infeciosa do trato inferior respiratório. Deste modo as formulações 
desenvolvidas foram: partículas sem fármaco: Unloaded LBG e partículas com fármaco 
(ratio polímero:fármaco), LBG.INH 10:1, LBG.RFB 10:0.2, 10:0.5, 10:1 e LBG.INH.RFB 
10:1:0.5 e 10:1:1.   
Apesar de a goma de alfarroba formar dispersões viscosas, devido a não solubilizar por 
completo, foi necessário a adição de ácido clorídrico (HCl) 0.1 M, para que fosse possível a 
sua atomização. Permitindo-se assim obter com um rendimento satisfatório (entre 58 a 
71%), micropartículas com tamanho adequado para a administração alveolar (entre 1.26 a 
1.50 µm). Para além do tamanho adequado, apresentam também valores de densidade real 
(aproximadamente 1.45 g/cm3) e de diâmetro aerodinâmico (entre 1.27 a 1.90 µm), que 
indicam a sua capacidade de atingirem a zona alveolar.  
Apesar de a INH ser um fármaco hidrofílico e a RFB ser um fármaco hidrofóbico, foi possível 
a sua encapsulação na matriz hidrofílica da LBG, com valores elevados de eficácia de 
encapsulação (> 82%). Outra justificação para a adição de HCl na formulação, foi a 
necessidade, de na molécula de RFB, haver um processo de desprotonação, que permitisse 
a sua solubilização em meio aquoso. O perfil de libertação de INH e RFB foi analisado a 
partir da formulação LBG.INH.RFB 10:1:0.5, verificando-se a libertação de ambos os 
fármacos num perfil semelhante em meio com pH 7.4, representativo da região alveolar. O 
perfil de libertação de INH a partir da formulação de LBG.INH foi avaliado, em dois meios, o 
representativo da região alveolar, e um representativo do fagolissosoma dos macrófagos, 
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pH 5, estrutura formada após a fagocitose da micropartícula, e onde se irá libertar o 
fármaco. Em ambos os meios se obteve um perfil de libertação rápido de INH.  
A biocompatibilidade dos fármacos, matéria-prima e sistemas micropartículados produzidos 
foi avaliada em duas linhas celulares, uma representativa do epitélio alveolar (A549) e outra 
representativa dos macrófagos alveolares (macrófagos diferenciados a partir de células 
THP-1). E é feita através da avaliação da atividade metabólica (MTT) e da libertação da 
enzima lactato desidrogenase (LDH). Os resultados obtidos nos dois testes foram 
concordantes entre si, e verificou-se que nas concentrações testadas o fármaco RFB é 
citotóxico, com um índice de concentração que inibe a proliferação/população celular em 50 
% (IC50), nestas duas linhas celulares, idêntico aos ratios testados. Apenas formulações que 
contêm RFB, se observa uma redução da viabilidade celular para estas duas linhas 
celulares, abaixo, do limite aceitável para formulações farmacêuticas (70%). No polímero 
observa-se alguma citotoxicidade nas células A549, que não está presente nas Unloaded 
LBG. Diversas razões foram apresentadas para a explicação desta citotoxicidade da RFB, 
sendo que por comparação com as Unloaded LBG MPs, se justifica, que a presença de HCl 
necessário na formulação, em associação com a RFB faz com que exista um efeito 
sinérgico na redução da viabilidade celular. É proposto a redução do ratio de RFB para um 
inferior aos desenvolvidos, usar HCl 0.01M para a sua encapsulação, e testar um novo 
excipiente para a redução da viscosidade da LBG.    
A biocompatibilidade foi também avaliada, quando os sistemas micropartículados são 
apresentados em aerossol. As micropartículas selecionadas foram as seguintes: Unloaded 
LBG, LBG.INH 10:1, LBG.RFB 10:0.5 e LBG.INH.RFB 10:1:0.5 na dose 303 µg/cm2, 
correspondente à concentração mais elevada em que amostras foram testadas quando 
apresentadas em solução. As micropartículas foram insufladas sobre uma monocamada de 
macrófagos alveolares. Como em todas se apresentou uma elevada redução de 
citotoxicidade, selecionou-se as Unloaded LBG e LBG.INH.RFB 10:1:0.5 e testou-se na 
dose 50 µg/cm2, verificando-se um aumento da viabilidade celular, em ambas, mas maior 
nas partículas brancas. Reforçando também, que as doses testadas são elevadas, 
comparativamente com a dose fármaco/sistema administrada in vivo, onde se esperam 
melhores resultados de viabilidade celular.  
Através de citometria de fluxo, foi analisado a capacidade de os macrófagos fagocitarem 
micropartículas com a matriz de LBG nas linhas celulares referidas. Onde se verificou a 
existência de uma elevada percentagem de fagocitose nos macrófagos diferenciados a partir 
de THP-1 (99,5 %), e nas NR8383, uma preferência significativa por micropartículas de LBG 
(94,35 %) comparativamente com um polímero sem mannose na sua estrutura (53,16%).  
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Após comprovada a capacidade dos macrófagos em fagocitarem micropartículas de LBG, foi 
avaliada a capacidade deste galactomanano em ativar macrófagos, diferenciados a partir de 
THP-1, e que se encontram no estado M0 de ativação, para o estado M1, com capacidade 
pro-inflamatória. Após a exposição destas células, á uma solução da matriz de LBG e de 
micropartículas de LBG.INH.RFB 10:1:0.5 na dose de 303 µg/cm2, verificou-se que, devido a 
sua estrutura, a LBG tem a capacidade de induzir a libertação de citocinas, factor de 
necrose tumoral α e interleucina 8, num nível idêntico ao lipopolissacarídeo, presente na 
parede bacteriana, e com num nível superior e estatisticamente significativo 
comparativamente com o nível basal.  
Estes resultados reforçam que as micropartículas obtidas a partir deste polímero, através de 
atomização, apresentam propriedades aerodinâmicas que permitem que atinjam a região 
alveolar, e sejam veículos de fármacos antituberculosos ou de um outro antibiótico. E devido 
a sua estrutura com mannose, permitem que haja um reconhecimento específico pelos 
macrófagos alveolares infetados, permitindo potenciar a sua fagocitose. Após este processo, 
estas micropartículas permitem a libertação dos fármacos em meio intracelular, e ainda, 
activarem os macrófagos, para um estado de ativação pro-inflamatório, que irá melhorar a 
resposta inflamatória, e consequentemente, um melhor controlo o agente infecioso.  
 
Palavras-chave: Administração pulmonar, goma de alfarroba, isoniazida, macrofagos 
alveolares, micropartículas, rifabutina, tuberculose. 
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Abstract  
Locust bean gum (LBG) is a polysaccharide composed of galactose and mannose residues, 
a composition that might be of interest in the ambit of pulmonary tuberculosis treatment. The 
polymer can be processed by spray-drying to produce microparticles that act as carriers for 
antitubercular drugs via inhalation.  Once in the alveolar region, where alveolar macrophages 
hosting Mycobacterium tuberculosis reside, these microparticles are expected to be 
phagocytosed by macrophages, then releasing the drugs in the intracellular compartment 
where the bacteria are located. Considering that alveolar macrophages have specific surface 
receptors recognizing preferentially mannose residues and also with affinity for galactose 
units, an improved targeting of antibiotic loaded microparticles towards the bacteria hosts is 
expected. 
In this work the production of LBG microparticles by spray-drying is reported for the first time, 
exhibiting adequate properties for inhalation with the aim of reaching the alveolar zone 
(aerodynamic diameters between 1.27 and 1.90 µm). Two different first line antitubercular 
drugs (isoniazid and rifabutin) were effectively associated to the microparticles (association 
efficiencies > 82%). The cytotoxicity of the drugs, raw material and carriers (unloaded and 
drug-loaded) was evaluated in A549 cell line and macrophage-like cell line (macrophage 
differentiated THP-1 cells). It was verified that RFB has a cytotoxic effect when tested as free 
drug and formulations containing the drug also revealed toxicity although to a lower 
extension. This cytotoxic effect was more pronounced at 24h and is both time- and 
concentration-dependent. LBG-based carriers were also exposed to macrophage-like cells in 
the form of aerosol, in a dose (50 µg/cm2) that was optimized to be more close to that applied 
in in vivo lung administration. Although the cell viability was not as lower for RFB-containing 
microparticles, some cytotoxicity was still observed. Additionally, the capture of 
microparticles by macrophage-differentiated THP-1 cells and NR8383 cells (rat alveolar 
macrophages) was evaluated by flow cytometry. In both cells lines, the microparticles were 
insufflated over a monolayer of macrophages at dose of 50 µg/cm2, where was verified a 
high percentage of phagocytose (> 94 %). The capacity of microparticles to activate 
macrophages (differentiated THP-1 cells) was also evaluated. The exposure to a dose of 303 
µg/cm2 microparticles was verified to have the ability to induce the release of cytokines 
(interleukin-8 and Tumor necrosis factor α), indicative of activation, at a level identical to that 
induced by the incubation with lipopolysaccharide.  
The obtained results as a whole indicate the ability of LBG to act as matrix of inhalable drug 
carriers produced by spray-drying. The microparticles demonstrated capacity to effectively 
associate model antitubercular drugs and suitable aerodynamic properties to reach the 
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alveolar zone. LBG microparticles further evidenced high ability to be captured by 
macrophages, which is very relevant regarding tuberculosis therapy.  
 
Key-words: Alveolar macrophages, antibiotic delivery, locust bean gum, microparticles, 
spray-drying, tuberculosis. 
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1. Introduction  
1.1. Infectious lung diseases and tuberculosis 
Lungs are a site for gas exchange, and their direct contact with the external environment 
facilitate the entrance of pathogens.1 This is the premise for  infectious lung diseases, which 
can be caused by bacteria, viruses and/or fungi.2 Respiratory bacterial infections are 
considered the major cause of death worldwide,1 a scenario that is getting worse because of 
increased antibiotic resistance.2 Some of the most popular air-borne diseases are tuberculosis, 
pneumonia and pertussis.3 The administered drugs have to reach the pathogens, which can 
be in different habitats, such as the mucus, biofilms or inside host cells.2 For instance, in 
pneumonia pathogens are in the mucus of bronchiolar or alveolar zone,2,4 for example, 
Streptococcus pneumoniae presenting virulence factor that favors the adherence to alveolar 
epithelia.4 In turn, in tuberculosis the pathogen lives inside macrophages, which are located in 
alveolar zone.5 Furthermore, different infections might occur simultaneously.6 As in many 
cases the therapeutic approach is made via oral antibiotherapy, the used doses are high and 
treatment periods are long, resulting in severe side effects with consequences at the level of 
patient compliance. Usually, a combination of antibiotics is needed to treat resistant 
pathogens. This is described, for instance, in multidrug-resistant tuberculosis (MDR-TB).2,7 
Cystic fibrosis (CF) is another relevant example. Although it is a genetic disease itself, it is 
associated with chronic lung infection.2 CF therapy thus implies the administration of 
antibiotics. The administration of antibiotics by inhalation is clinically implemented in this 
disease8 and this modality has been described to increase the therapeutic efficacy, while 
minimising the risks of bacterial resistance and preventing patient re-infection.9 This inhalation 
strategy, however, is not clinically implemented in tuberculosis therapy. However, there are 
possibly lessons to be learnt from the experience of the CF community.  
Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis 
(M. tuberculosis). This pathology is highly contagious, as the bacillus spreads out in the air 
when people having pulmonary TB expel it by coughing. It is, thus, disseminated via inhalation 
of bacteria-containing droplets. It affects primarily the lungs and pulmonary TB represents 80% 
of cases.7 However, TB does not  affect this organ exclusively, as extrapulmonary TB affects 
other organs, mainly the central nervous and the circulatory systems.1,10,11  
The current therapy of pulmonary TB consists in a six-month regimen of four first-line oral 
drugs, having a success rate of around 85%.10 Treatment failure is frequently associated with 
lack of patient adherence to the drug regimen and to MDR-TB. This failure leads to rapid 
growing of MDR-TB and extensively drug resistant (XRD) strains,1 which are considered a 
world-wide threat because of high risk of transmission.7,12 The MDR-TB treatment requires 
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second line drugs, which are less effective and poorly tolerated.2 Prevention of resistant 
tuberculosis needs adequate treatment of each case of TB and improvement in the 
compliance.10 New anti-tubercular drugs and new administration systems are needed to 
address MDR-TB strains and to increase antibiotic efficacy.2 MDR-TB is defined as resistance 
to at least rifampicin (RIF) and isoniazid (INH), the two most powerful antitubercular drugs, 
while XRD corresponds to MDR-TB plus resistance to at least one fluoroquinolone and a 
second-line injectable antibiotic.13 
 
1.1.1. The epidemiology of tuberculosis infection 
In 1993 TB was declared a global public health emergency by the World Health Organization 
(WHO), a distinction never granted to any other disease.1 This disease remains a major global 
health problem, and it ranks as the second leading cause of death from an infectious disease 
worldwide, after the human immunodeficiency virus (HIV).2 In 2012, the WHO estimated 8.6 
million new TB cases, mainly in Asia (58% of the new cases) and Africa (27%), and 1.3 million 
of people died of TB.10 Patients with HIV, due to a compromised immune system, have a 
higher risk to develop active TB. About 0.47 of the 1.3 million deaths were of patients with HIV 
associated to TB.1 
Without treatment or its failure, TB mortality rates are high, with 70% of infected people dying 
within 10 years.10  In the 1.3 million of deaths registered in 2012, about 170,000 arose from 
MDR-TB, a relatively high number compared with 450,000 incident cases of  MDR-TB in this 
year.10 
A worrying number is that of asymptomatic people infected with M. tuberculosis. These 
people, staying in a latent state of the disease, are estimated to make up to one-third of the 
global population,2,14 representing an enormous reservoir of potential disease. It is estimated 
that about 5 -10% of people with latent TB will develop active disease.14 
 
1.1.2. Tuberculosis pathogenesis 
Humans are the primary host of M. tuberculosis, which is disseminated via inhalation of 
bacteria-containing droplets. People suffering from pulmonary or laryngeal TB can disseminate 
the disease by emission of droplets containing the tubercle bacilli from cough, sneeze, shout 
or sing. These airborne particles have 1 to 5 µm, depending on the environment, and may 
keep suspending in the air for several hours. Upon inhalation and given their size, the 
infectious droplets can reach the alveolar zone, where they are phagocytosed and accumulate 
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inside alveolar macrophages to form granulomas in a later stage.10,15 The pathogen M. 
tuberculosis might exist as actively dividing bacilli (active disease state) or in the so-called 
“dormant” state. In the latter case, people are infected but clinically asymptomatic, and are 
referred to have latent tuberculosis.14 The dissemination of the disease through the infected 
droplets occurs only from individuals with active disease.22 Both states can occur within the 
same infected individual, depending on the stage of TB. Although the human immune system 
can control the infection, this control does not lead to complete elimination of bacteria, they 
just stay in the referred dormant state.7 In these cases, mycobacteria survive in a structure 
called granuloma, with no adverse effect on the health of the host, even up to the life time.15  
M. tuberculosis is an intracellular bacterium and alveolar macrophages (AM) are its “favorite” 
host, although it can affect other cell types,14 resulting in extrapulmonary tuberculosis. The 
granuloma structure probably represents a balance between active and latent TB.15 If a 
deterioration of host immunity occurs in a person with latent TB, there is increased probability 
of developing the disease.16 Only about 10% of infected people develop TB, because in most 
healthy individuals, the immune defense system is sufficient to eliminate mycobacterium at the 
initial stage, which has a duration of 4 to 6 weeks.14 Figure 1.1 resumes the whole process of 
TB pathogenesis, since infection, initial stage and progress for adaptive immune response with 
granuloma formation, and propagation of the disease.  
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Figure 1.1: Tuberculosis pathogenesis. Infection is initiated by the inhalation of droplets that contain 
bacteria. The first immune response is innate and involves the recruitment of inflammatory cells. In 
lymphoid node, dendritic cell presentation of bacterial antigens leads to T cell activation, and these cells 
recruit more cells. These cell agglomerates lead to the establishment of granulomas. Some individuals 
can control the infection, remaining in a “latent” state. A small percentage of these people will eventually 
progress and develop active disease, which can lead to the release of M. tuberculosis from granulomas 
that have eroded into the airways. Adapted from Nunes-Alves et al..14  
 
M. tuberculosis and seven very close species of Mycobacterium gender (M. bovis, M. 
pinnipedii, M. canetti, M. affricanum and M. mungi, M. microti and M. caprae) belong to the so-
called M. tuberculosis complex. Some of them may cause the disease in humans.10 When M. 
tuberculosis is phagocytosed by macrophages, a series of phenomena occur, including 
membrane invagination, budding, and fusion events, that finally result in the formation of a 
phagosome. Bacilli are distributed further within the cell through a series of vesicle trafficking 
events delivering the material to the antigen processing and presentation pathway. When 
endosomes gain endolithic capacity they are designated as lysosomes. These vesicles then 
fuse with the phagosomes, forming the phagolysosomes, where extensive degradation occurs 
resulting in clearance of potentially harmful material and subsequent destruction of 
pathogens.7,14 Infected macrophages  can  remain  in  the  lung or disseminate to other organs 
in the body.7 
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The binding of M. tuberculosis with the phagocytes is mediated by complement receptors 
(CR1,  CR2,  CR3  and  CR4),  mannose receptors  (MR),  dendritic  cell-specific  intercellular  
adhesion  molecule  (ICAM)-3-grabbing  nonintegrin  (DC-SIGN),  and  Fc  receptors. The 
complex structure of the macrophage cell surface is accountable for the capacity of multiple 
receptor molecules to internalize mycobacterium.7 In the initial stages of the infection, after 
phagocytosis by alveolar macrophages, an innate immune response is developed. If the 
appropriate stimuli are activated, transference of the phagocytosed bacilli to the destructive 
phagolysosome occurs. However, some bacilli are able to escape lysosomal delivery and 
survive within the macrophage.7 After phagocytosis the fate of M. tuberculosis can assume 
three distinct possibilities: a) escape from phagosome, b) prevent phagosome-lysosome fusion 
or c) survive inside of phagolysossomes.17  When inside the phagosome or phagolysosome, 
M. tuberculosis has the ability to encode a number of enzymes involved in lipogenesis and 
lipolysis. These enzymes will interfere with lipidome of host cell causing modifications, which 
involve cell signalling traffic membrane, lipid storage in lipid droplets and fusion organelles. 
Allowing inhibition of activity phagolysosome in the host cell and apoptosis, also, there is a 
lipid delivery resource for mycobacterium. These mechanisms will also permit maintenance, 
survival and replication (Figure 1.2).18  
 
Figure 1.2: Effects of mycobacteria on the host cell lipidome. LD: lipid droplet; S1P: sphingosine-1-
phosphate; SapM: M. tuberculosis effector molecule; PI(3)P: phosphatidylinositol-3-phosphate; EEA1: 
Early endosomal antigen 1; PI(3)K/Vps34: phosphoinositide 3- kinase; PIM: phosphatidylinositol 
mannoside; ManLam: mannose-capped form of Lam (lipoarabinomannan); ER: endoplasmic reticulum; 
TACO: tryptophan aspartate containing coat protein. Adapted from van der Meer-Janssen et al..18 
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Before the infection by M. tuberculosis, alveolar macrophages are said to be in steady-state 
conditions, as they have not yet been activated (assumed as M0 activation state).  Based on 
their function, activated macrophages are divided broadly into two categories: classical M1 
and alternative M2 macrophages. When a M. tuberculosis infection occurs, macrophages 
generally activate towards a M1 phenotype in the early stage of the infection.19 When 
macrophage receptors recognise the mycobacteria, the activation leads to the production of a 
high amount of pro-inflammatory mediators (interleukin(IL)-1, tumour necrosis factor (TNF)-α), 
which eliminate the invading organisms and activate the adaptive immunity.17 To counteract 
this excessive inflammatory response, macrophages undergo apoptosis or activate to an M2 
phenotype to protect the host from excessive injury and facilitate wound healing.17,19   
The induction of adaptive immune response occurs later, when M. tuberculosis disseminates 
to lymph nodes. The presentation of bacterial antigens by dendritic cells leads to priming and 
expansion of antigen-specific T cells, which differentiate from naïve T cells into effector T cells 
(T CD4+ cells). In parallel, the pro-inflammatory mediators (transforming growth factor (TGF)- 
and Interleukin-12) stimulate the migration of THelper cells.20 These cells migrate to the infected 
lung, and, in association with other leukocytes, induce the formation of granulomas.14 The 
activation of macrophages is also mediated by secreted by CD4+ T cells. These T cells secrete 
cytokines and chemokines, thus keeping the macrophages in an activated state and ensuring 
the recruitment of other immune cells to the site of infection.7 As an example, dendritic cells 
are also recruited to the lungs in order to complement the bactericidal effect of macrophages.14 
Additionally, the activation of macrophages is expected to restrict the dispersion and 
replication of M. tuberculosis. In the granuloma, macrophages can coexist in M0, M1 and M2 
state of activation.7 Figure 1.3 exposed the interaction between these cells in formation of 
granuloma. 
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Figure 1.3 Persistent infection with M. tuberculosis. (a) Infecting mycobacteria taken up by alveolar 
macrophages in the lung resist killing by subverting phagosome maturation. (b) Inflammatory signaling 
in response to mycobacterial components results in the recruitment of T cells. T cell−mediated 
activation of macrophages enhances their ability to control mycobacteria. (c) Remaining viable 
mycobacteria are sequestered within a granuloma made up of macrophages and a variety of T cell 
subsets. (d) M. tuberculosis is able to persist in an asymptomatic form within the host. (e) Reduced 
immunity is associated with reactivation disease. Adapter from Young et al..20 
 
Granulomas are important structures in the pathogenesis of tuberculosis.7  These are very 
organized structures where M. tuberculosis resides within macrophages for a long time in a 
dynamic process.16 Where infected macrophages begin the apoptosis process, can occur their 
elimination through phagocytosis by newly macrophages that were attracted to the 
granuloma.15,16 They organize in clusters, containing infected macrophages in the centre, 
surrounded by macrophages, epithelioid macrophages, giant cells, dendritic cells, 
lymphocytes, neutrophils and fibroblasts.2,5,7,15  
 
1.1.3. Antitubercular drugs 
The goals of chemotherapy include cure without subsequent relapse, impediment of 
mycobacterium transmission, to minimize risk of death and disability, and prevention of drug 
resistance.10 To achieve these goals, a long-term treatment is required, with a combination of 
drugs. The antitubercular drugs have different mechanisms of action and targets, which allow 
complementarity and an increase in the rate of efficiency. The antibiotics used in TB treatment 
are from different classes of antibiotics and have been classified as follows: 
THelper cell 
Fibroblast 
Lymphocyte B 
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a) First-line antitubercular agents: RIF, rifabutin (RFB), INH, pyrazinamide (PZA), 
ethambutol and streptomycin; 
b) Second-line antitubercular agents: ethionamide; fluoroquinolones (e. g. 
levofloxacin), aminoglycosides (e. g. capreomycin), para-aminosalicylic acid, and 
cycloserine; 
The current recommended TB chemotherapy is a six-month regimen of four co-administered 
drugs in a directly observed treatment, ((DOTS) short-course)).  For TB the following multi-
drug therapy has been applied: 
a) An initial intensive phase of INH, RIF, PZA, and ethambutol daily for 2 months. A 
subsequent phase of RIF and INH for further 4 months, either daily or three times per 
week.7,10 
The initial intensive phase aims at reducing the rapidly diving bacilli load. In the second phase, 
a combination of two or three drugs for at least 4 months, is necessary to sterilize lesions 
containing fewer and slow—growing bacilli.10  
Figure 1.4 indicates on the left current antitubercular drugs and their respective targets in M. 
tuberculosis. On the right side, new targets for potential drugs are indicated.7 New targets and 
new drugs are necessary due to the emergence of MDR and XDR strains, the associations of 
drugs, with different mechanism of action, has the objective of raising the efficiency of 
treatment.  
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Figure 1.4: Scheme of drug targets in Mycobacterium tuberculosis. The targets that can be 
inhibited by existing drugs in the left and new targets in right side. Fatty acid synthase (FasI), enoyl-
acyl-carrier protein-reductase (InhA), b-ketoacyl ACP synthase (KasA), arabinosyltransferase (EmbAB), 
D-alanyl-D-alanine ligase (Ddl), DNA dependent RNA polymerase (RNA pol), DNA gyrase and 
ribosome are shown as targets inhibited by existing drugs used to treat TB. Recently identified targets 
include maltosyltransferase (GlgE), ATP synthase, L,D-transpeptidase (Ldt), decaprenylphosphoryl-b-D-
ribose 20-epimerase (DprE1/E2), ATP phosphoribosyl transferase (HisG), mycothiol ligase (MshC), 
mycolic acid cyclopropanation, DosR(DevR), CarD, methionine aminopeptidase (Fmt), deformylase 
(Def), the proteasome complex and isocitrate lyase (Icl). Reprinted from Reference 25.  
 
INH is a prodrug and must be activated by bacterial catalase. Specifically, the activation of this 
enzyme is associated with the reduction of the mycobacterial ferric KatG catalase-peroxidase 
by hydrazine and reaction with oxygen to form an oxyferrous enzyme complex.7,10  Inhibin α 
(InhA), a NADH-dependent enoyl-acyl-carrier protein-reductase, present in M. tuberculosis, 
and was initially identified as the target of isoniazid.21 Once activated, INH forms a covalent 
adduct with the NAD cofactor. It is the INH-NAD adduct that acts as a slow, tight-binding 
competitive inhibitor of InhA. This inhibition blocks reductase of fatty acid synthase II (InhA) in 
mycolic acid biosynthesis, essential components of the bacterial cell wall.22 At therapeutic 
levels, INH is bactericidal against actively growing intracellular and extracellular 
Mycobacterium tuberculosis organisms.23  
RFB belongs to the group of rifamycins, sharing the same mechanism of action.7 It inhibits 
bacterial ribonucleic acid (RNA) synthesis by binding to the -subunit of bacterial  
deoxyribonucleic acid (DNA)-dependent RNA-polymerase, leading to blocking of the  initiation 
chain formation in message RNA synthesis,7,10,21 and, consequently, leading to death of M. 
tuberculosis. 24  
Although RFB is preferable to RIF because of the superior in vitro activity and the decreased 
risk of drug interactions,25 RIF is mostly used due its lower cost comparatively with RFB.26 RFB 
has been indicated by WHO, in the Guidelines for MDR-TB treatment, which include RFB as 
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first-line oral agent due to its potency and efficacy. This drug is strongly recommended for the 
treatment of HIV patients having TB.13  
For the work presented in this thesis, INH and RFB were chosen as model antitubercular 
drugs. INH is a hydrophilic drug and its chemical structure is depicted in Figure 1.5 A. It has a 
molecular mass of 137.14 g/mol and the solubility is 1.4 x105 mg/L (25 ºC).23 In turn, RFB is a 
lipophilic drug (Figure 1.5 B), with molecular mass of 847.01 g/ml and minimal solubility in 
water (1.9 x 10-4 mg/mL). Annex I presents a complementary characterisation of these drugs. 
 
Figure 1.5: Structure and chemical formula of Isoniazid and Rifabutin. Adapted from DrugBank.23,24 
 
1.2. Pulmonary drug delivery 
Pulmonary drug delivery is a relevant approach in the treatment of respiratory diseases, as it 
allows direct targeting of the therapeutic agents to the site of action. As compared with a 
systemic delivery mediated by the oral or parenteral routes, pulmonary delivery permits site-
specific drug deposition at high concentrations. In many cases, this local drug delivery is 
reported to reduce systemic exposure to the drug and, consequently, the occurrence of 
systemic side effects. Additionally, it provides the possibility of obtaining drug therapeutic 
effect with lower dose comparing with oral delivery, further permitting a more rapid 
response.27,28 Inhalable therapy for the treatment of asthma and chronic obstructive pulmonary 
disease has been established and routinely used for decades.29 
Systemic delivery of therapeutics via the lungs has been also investigated, mainly due to the 
identification of several advantageous characteristics of the lung for this effect. These 
characteristics include a high surface area (80 – 100 m2) available for absorption in the 
alveolar region, strong irrigation and a highly permeable epithelium for the absorption of drugs 
into systemic circulation.28 Drug molecules are absorbed more efficiently from the lung than 
from any other non-invasive routes of drug administration. Pulmonary route offers multiple 
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advantages over oral route for large protein molecules, for instance, allowing to eliminate the 
degradation associated to the gastrointestinal tract and the first-pass effect.28 For example, 
insulin and antigens have been tested in different carriers for pulmonary administration,12 and 
insulin is currently available as inhalable product. 
Inhaled drugs are becoming increasingly available on the market to treat various diseases, 
reflecting the advantage of the non-invasiveness of the route and the acceptance by the 
patient.27   
 
1.2.1. Lung deposition 
The effectiveness of an inhaled therapy is dependent of the aerosol characteristics, lung 
morphometry and pulmonary physiology. The site of deposition of an aerosol depends on its 
ability to reach a determined zone, which is strongly related with its aerodynamic proprieties, 
but also depends on the breathing pattern of the patient.27 The aerodynamic properties are 
mainly defined by the aerodynamic diameter (Daer), a parameter commonly referred in the 
ambit of dry powder formulation, which congregates the contribution of both the geometric size 
of a particle and its density. The theoretical definition indicates that the Daer of a particle is the 
diameter of a spherical particle of unit density (0) which settles at the same terminal velocity 
as the particle in question.30 There are several slightly different formulas enabling a theoretical 
calculation of this parameter. One of the most used in recent years is the following, which 
considers not only particle geometric size and density, but also its shape:27 
     
Where d is the geometric diameter of the particle, real is the real density, 0 is unit density, and 
 is the dynamic shape factor denoting deviation of shape from sphericity.30  
Particle size is a parameter of major influence in lung deposition (Figure 1.6). Large particles 
(> 10 µm) are reported to deposit in the upper airways (mouth, oropharyngeal and pharynx) by 
inertial impaction. When the size is between 5 and 10 µm, the deposition mainly occurs in the 
trachea and bronchi. Particles with a size within 0.5 and 5 µm deposit by gravitational 
mechanism (see below) and reach deeper areas. Sizes between 2 and 5 µm are mainly 
deposited in bronchioles, while fine particles (< 2 µm) mostly reach the alveolar zone, where 
they can be phagocytosed by macrophages (0.5 – 2 µm).31 Smaller particles are mostly 
exhaled,27 although some of them might deposit by Brownian diffusion in the alveolar region. 
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The latter results from the random movements of colloidal particles caused by collision with 
gas molecules.32 
 
Figure 1.6: Particle deposition in the lungs according to size. Adapted from Nahar et al.33  
 
The mechanisms of deposition are variable and depend on the lung region and particle 
physical parameters. Depending on their aerodynamic diameter, three mechanisms of 
deposition have been described: (1) inertial impactation, (2) sedimentation, (3) diffusion.1 
Figure 1.7 illustrated the three main mechanisms (from 1 to 3).  
 
Figure 1.7: Main mechanisms of particle deposition in respiratory tract. Reprinted from reference 
1. 
Large particles are unable to maintain the movement on air stream due to their large size. 
Therefore, they tend to preferentially deposit in upper airways and tracheobronchial airways, 
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by inertial impaction. Smaller particles deposit by gravitational sedimentation in the 
tracheobronchial tract. Particles with Daer of 0.5 to 1 µm are subject to Brownian diffusive 
deposition. Some of these, as well of those having less than 0.5 µm will possibly be exhaled.   
Finally, it is important to mention that the mechanism(s) of deposition affecting a single particle 
might be influenced by the patient breathing pattern and, more specifically, its rate. Slow 
inhalation benefits the deposition of large particles, which normally deposit by impaction, 
allowing their increased penetration into lungs. In turn, smaller particles are much less 
sensitive to fast/slow inhalation variations. Additionally, a breath hold favours the capacity of 
particles to penetrate deep into the lungs and to sediment on airway surfaces.27   
 
1.2.2. Pulmonary administration 
Pulmonary administration of drugs must be done using an inhalation system and, in recent 
years, it has been considered advantageous to use suitable vehicles to carry the drugs. The 
ideal device must generate an aerosol with suitable size for the intended objective of the 
administration, allowing reproducibility of drug dosing. Regarding the carrier, this is required to 
protect the drug formulation from the point of view of physical and chemical stability, 
evidencing a good aerosolisation pattern and reaching the desired site of action or absorption, 
features that are dependent on the aerodynamic properties. Moreover, the ideal inhalation 
system (device) must be simple to use, convenient, portable and inexpensive.34 
The inhalation device might work with formulations under solid state (Dry Powders Inhalers – 
DPIs) or under liquid state. In the latter, Metered Dose Inhalers (MDIs) or nebulisers are the 
available systems.35 Nebulisation is reported as the easiest administration mode to deliver 
aqueous solutions or suspensions of drugs of interest, namely antibiotics.36 In this regard, 
tobramycin and aztreonam solutions have been approved in Europe for nebulisation in the 
ambit of CF.37  
Nebulisers were the first inhalation devices available in the pharmaceutical market,34 and the 
delivery is considered to occur under a controlled rate.35 During nebulisation, liquid aerosols 
are generated by mechanical or electrical mechanisms. These devices have advantages, as 
they are easily used in all ages, from new-borns to the adulthood, including when patients are 
breathing tidally.9 Moreover, they generate the aerosol with great efficiency, allow drug 
administration in high doses and independently of the breathing pattern of the patient.34 
However, some important disadvantages apply, as the administration by nebulisation is a time-
consuming process (average of approximately 30 minutes) with simultaneous drug 
administration and clearance possibly occurring in this period, and presents poor 
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reproducibility. Moreover, medication preparation and time dedicated to equipment 
maintenance are long, associated to uncomfortable transport of the device. 
Metered Dose Inhalers are devices using an aerosol propellant and a dose-metering valve to 
regulate the exit of defined doses by inhalation. These devices are extremely portable, a great 
advantage comparing with nebulisers, but require patient training to coordinate inspiration and 
actuation of the device. A long period between emission of the aerosol from the device and the 
beginning of inhalation leads to wastage of a proportion of the emitted dose.38 Thus, poor 
coordination of actuation and inhalation, associated to high particle exit velocity, are 
parameters leading to major dose losses. The deposition of an aerosol in the upper airways 
can vary considerably according to the application technique. In MDI devices, losses of 
aerosol are routinely great than 70% and can exceed 90% and, consequently, the 
effectiveness of current aerosol therapy protocols are compromised.34  
Dry Powders Inhalers (DPIs) were developed as an alternative to the previously described 
devices, presenting the great difference (and also advantage) of providing the drugs in solid 
state, in the form of dry powders.38 As MDIs, DPIs are portable, but do not use propellants, 
instead combining powder technology with device design to disperse dry particles as an 
aerosol in patient’s inspiratory airflow.34 Studies have revealed improvement of treatment 
efficiencies and patient adherence as compared with nebulisers.36 Again in the ambit of 
antibiotic delivery, tobramycin DPI has shown better results comparing with the nebulized 
formulation.9  
The advantages of DPIs over other devices are noticeable. Apart from the referred portability 
and quick administration, DPIs are easy to use and maintain. The formulations, in dry powder, 
are more stable as compared with liquid counterparts,12 do not require refrigeration and the 
maintenance of formulation sterility is ensured during the life-time of the device content, which 
is an important consideration for patients frequently highly susceptible to  lung infection.9 
These advantages contribute to increased treatment efficiency and patient adherence, which 
was demonstrated for instance with the tobramycin DPI.36 Naturally, DPIs also present 
disadvantages, the most important being a consequence of the proper actuation mechanism. 
As the inhaled dose is removed from the device by the inspiration of the patient, the aerosol 
characteristics and the lung deposition are highly dependent on the inhalation profile 
generated by the patient through the DPI. In this regard, forceful inhalation generates high 
inspiratory flows and possibly results in high deposition in upper airways, which can induce 
cough. Contrarily, slow and deep inhalation has been reported to improve the deposition into 
small airways, reducing upper airway deposition.9  As a relevant feature, dry powders have a 
tendency to undergo particle agglomeration, increasing the aerodynamic diameters and, thus, 
lowering the respirable fractions. As a consequence, a lower number of particles reaches the 
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alveolar zone, which might affect the therapeutic effect of any formulation requiring reaching 
that zone, such as formulations aiming at a systemic effect or a local effect in the alveolar 
zone.31 Another disadvantage of DPI concerns the amorphous or partly amorphous pattern of 
powders produced by spray-drying, a technique frequently used for their formulation. In that 
case, physical and chemically instability might arise, principally under conditions of high 
humidity.36  
 
1.3. Inhalation as a strategy in tuberculosis therapy 
The use of inhalable dry powders has been proposed in the context of tuberculosis therapy. 
The main interest is the formulation of INH, RIF, RFB and PZA dry powders, for their 
applications against MDR-TB and XDR, as it is expected that higher local concentrations of 
these drugs can be reached via the pulmonary route.13 This approach might make resistant 
mycobacterium strains more susceptible to these drugs.5 New drugs like TMC207, PA-824 and 
BTZ043 are in development for TB therapy and could also be interesting for pulmonary 
administration,12,38 but so far no studies on their delivery through the lung route are 
available.12,39 The use of new drugs, new formulations and the exploration of alternative routes 
of administration, other than the oral route, are necessary and urgent in order to revert the 
increasing bacterial resistance of M. tuberculosis against a growing number of currently used 
antitubercular drugs. 
Different formulations and carriers are reported in the literature to provide good in vivo results 
regarding bacteria elimination upon inhalation. As an example, RIF, INH and PZA were loaded 
in alginate-chitosan nanoparticles by Zahoor et al.40, formulation presenting a high 
encapsulation efficiency (> 70%). About 80% of the nebulised formulation presented a suitable 
aerodynamic diameter for inhalation (1.1 ± 0.4 µm). Biodistribution studies performed in guinea 
pigs evidenced plasma bioavailability for a period exceeding 10 days, and concentrations 
higher than the minimum inhibitory concentration for up to 15 days in the main affected organs 
(lungs, liver and spleen). The formulation allowed increased drug residence time in the 
infection site comparing to free drugs. Chemotherapeutic studies in infected animals during 15 
days (three nebulised doses) revealed a comparable result with 45 daily doses of free oral 
drugs, resulting in undetectable mycobacterial colony forming units in lung and spleen 
homogenates. Nanoparticles were also found to not elicit signs of hepatotoxicity, supporting 
their safety.40 
 Another relevant example concerns the use of liposomes. For example, INH-entrapped 
liposomes of dipalmitoylphosphatidylcholine presented about 750 nm in diameter and 
associated INH with efficiency of around 37%. In vitro alveolar deposition using the twin 
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impinger exhibited about 25-27% of INH deposition in the alveolar chamber upon one minute 
of nebulisation. Results further showed the biocompatibility and antimicrobial activity of the 
formulation.41  
Notwithstanding the interest of the above formulations, dry powder formulations are frequently 
referred as the most adequate, particularly when lung delivery is at play. Several arguments 
can be used in favour, which include higher stability, low price, and disposable devices 
enabling the use in developing countries, where MDR and XDR-TB prevalence is higher.10, 36, 
42 Again, the literature displays many examples of dry powders proposed for tuberculosis 
therapy. Most of them are based on synthetic polymers. A relevant example is comprised of 
polylactic-co-glycolic acid (PLGA) microparticles encapsulating RIF. Spherical RIF-PLGA 
microspheres had Daer of 1.9 µm and were taken up efficiently by NR8383 cells (rat alveolar 
macrophages). Fluorescent microscopic analysis has shown that RIF-PLGA microparticles 
were localized in phagolysosomes, and then degraded.43 
There are many methods to produce dry powders, which include spray-drying, freeze-drying 
and emulsification-based techniques, among others. Depending on the used technique, either 
hydrophilic or hydrophobic drug molecules might be integrated in the formulations.12 In 
occasions, both types simultaneously.44 Drug physicochemical properties should be taken in 
account and, ideally, drugs inhaled as dry powders should be crystalline for maximal stability.42 
Spray dried, spray–freeze dried and freeze dried powders are obtained from solution and, due 
to the rapid drying, they are mostly amorphous.36,42 These are more susceptible to water 
uptake, which may lead to re-crystallisation and solid bridge formation between the particles, 
which does not benefit powder dispersion.12 The chemical nature of a drug can also influence 
the resulting dry powder properties,42 such as cohesiveness, flowability and compatibility, 
which interfere in the dispersion efficiency and retention in the inhaler, as well as on the size, 
surface properties and shape distribution.12   
 
1.3.1. Spray-drying to produce inhalable dry powders 
Spray drying (SPD) has been frequently used to produce dry powders with suitable properties 
for lung inhalation and presents the great advantage of permitting scaling-up.36 A spray-dryer 
can be operated in different modes: open cycle, closed-cycle and semi-closed cycle with or 
without aseptic conditions.45 The open cycle consist in intakes of drying gas from atmosphere 
and the expulsion of air into atmosphere after separation of microparticles by a cyclone. The 
closed-cycle operates with formulations containing flammable solvents. Semi-closed cycle is 
an intermediate between open and closed cycle dryers. In this system the drying gas is 
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recycled and it has a very low oxygen content, making it suitable for materials that cannot be 
exposed to oxygen, either because of risk of explosion or product degradation.46  
SPD process consists of four steps, as described in figure 1.8: (a) atomization of a feed 
solution or suspension into a spray; (b) warm spray-air interpenetrating into flow; (c) drying of 
sprayed droplets at elevated temperatures; and (d) separation of dried product from the air in 
cyclone.45 Obtained powders are collected in the product vessels.47 In figure 1.8 is 
schematized the operating mode of Spray dryer mini B290.48 
 
Figure 1.8: Scheme of the Buchi B-290 Mini Spray dryer. The figure shows an open-mode. Solution 
or suspension with drugs/proteins and carriers get in nozzle where a spray is formed. (a) The drying gas 
is heated at a defined temperature (Inlet T) and interpenetrates into flow (b), (c) the droplets are dryed 
in a drying chamber, (d) and enter the cyclone, where they are separated by helical motion of the air 
flow. (e) The obtained powder is collected in product vessels. (f) Outlet temperature is recorded after 
evaporation of the solvent. Reprinted from reference 48.48  
 
Spray-drying is a cost-effective particle engineering technique that permits the modulation of 
MPs characteristics, namely geometric size, density, and shape. An adequate combination of 
these parameters enables the production of MPs with suitable aerodynamic properties for 
pulmonary delivery.45 To the optimization of the final microparticles product should be tested 
different combinations between the operating parameters, such as drying temperature (inlet) 
and flow rate of drying gas, feed properties, feed rate, pressure and amount of atomizing air 
into drying chamber.45 The combination of these parameters, which might be adjusted by the 
operator, will influence the following parameters: droplet size, outlet temperature of air, drying 
efficiency and physical properties of final product, as particle size, moisture content and 
hydrosocopicity.49  
Locust bean gum-based microparticles for pulmonary delivery of antibiotics | 2015 
 
Master dissertation in Biomedical Sciences | 18  
 
Some parameters are more important than others and have a major impact in the process. 
The difference in the inlet and outlet temperature, and the percentage of liquid in the 
formulation are the driving force for the drying process.48 These two parameters are 
interdependent. Spray dryer dimension and the drying airflow rate are determinant on the 
residence time of the droplets in drying chamber, which influences the drying time. The volume 
of atomized droplet has a control over particle size, and the solution or suspension 
concentration control the average density.47   
Particle shape/morphology can be controlled by varying the feed solvent, where a mixture of 
alcohol and water can be included, or adjusting the outlet drying temperature.47 Atomization 
rate and feed concentration can be concomitantly wrought to generate particles with different 
degrees of surface corrugation. The production of particles with a rough surface might be 
achieved by the inclusion of common excipients, such as polysorbate 20 and lactose.45 The 
addition of some excipients such as leucine or mannitol can improve dispersibility. Adding 
leucine to the feed solution leads to weaker particulate interactions, due to the low surface-
energy leucine that forms a rough shell or coating on the outer surface of spray-dried 
particles.36  
SPD can be further adjusted for better product recovery and larger production scale, 
particularly for thermolabile materials such as proteins and peptides. Design of high-efficiency 
cyclone separation is crucial for this engineering to be economically acceptable on an 
industrial scale.45 This technique can be rendered more versatile by suitable modification to 
select specific needs.48 For example, the dryer can be adapted to aseptic processing of heat 
sensitive materials by ultrasonic atomization of feed solution into an atmosphere under 
reduced pressure to aid removal of the solvent at a much lower temperature.45 This technique 
has been employed for the manufacturing of inhaled proteins, for example, insulin (Exubera®, 
Pfizer), or antibiotics (Tobramycin TOBI® Podhaler®, Novartis), or for the development of 
microparticles, such as PulmoSphere™ technology.36  
SPD is a particle engineering technique that allows microencapsulation of proteins, 
thermolabile and/or hygroscopic drugs,36 and the amount of solvent in the final product is 
residual comparing with other techniques.34 
 
1.3.2. Matrix materials for inhalable dry powder formulations 
Biopolymers have been widely explored as matrix materials of drug carriers, owing to 
structural flexibility, biocompatibility and biodegradability.50 The non-immunogenicity and non-
cytotoxic properties of many polymers are preferential for applications in biomedical 
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sciences.51 Furthermore, the possibility of undergoing enzymatic or hydrolytic degradation 
becomes an eligible mechanism for controlled drug release. It is also necessary that the 
degradation products are biocompatible.52 Natural polymers have great advantages over 
synthetic polymers, not only because they are in principle more prone to biodegradability and 
biocompatibility, but also because they exhibit structural flexibility and are readily available at 
relatively low prices.53 Moreover, they are easily modified by simple chemical reactions52 and 
their processing for drug carrier production usually does not involve organic solvents, as 
happens with synthetic polymers, because of the hydrophilic nature. Therefore, there is no 
need to eliminate solvent residues and associated production costs are decreased. Natural 
polymers, however, present some disadvantages, which include the inter-batch variability, as 
well as complex and varied composition and low mechanic properties.11  
Polysaccharides have been marking a strong position in the biomedical field, due to their 
favourable physical properties and the chemical structure that allows applications in different 
areas, such as drug delivery, tissue engineering and diagnostic. They can be used as 
emulsifying, gelling, hydrating, thickening and suspending agents in diverse applications in the 
above cited areas.51 
Regarding the formulation of new carriers with application in inhalable tuberculosis therapy, 
synthetic polymers belonging to the group of polyesters take the leadership of proposals.12 
Particularly, polylactic acid (PLA) and PLGA are the most envisaged.10,52 However, because of 
the properties that were mentioned above for natural and synthetic polymers, using the former 
could be advantageous. Natural polymeric carriers might be produced involving in their 
matrixes polysaccharides, polynucleotides and proteins.  Polysaccharides are cheaper 
materials having a very flexible structure and have been used very frequently in drug delivery 
in general, and also in the particular application of tuberculosis inhaled therapy.11  
Polysaccharides are saccharide polymers that are composed of saccharide units linked 
together by glycosidic unions.54 The basic units composing these polymers are mainly D-
glucose, D-frutose, D-galactose, L-galactose, D-Mannose, L-arbinose and D-xylose, although 
D-glucose is the most frequently found. Some polysaccharides further present 
monosaccharide derivatives in their structure, such as simple sugar acids (gluronic acid and 
iduronic acid) and the amino sugars D-glucosamine and D-galactosamine and their 
derivatives, such as N-acetylneuraminic acid.51 The specific monosaccharides and their 
derivatives, the degree and steric configuration of the substitutions, the linkages and the final 
molar mass, are some of the features of polysaccharides dictating their specific 
physicochemical properties, such as solubility and viscosity, as well as the bioactive 
properties.53 
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Polysaccharides are many times divided in groups according to their composition, for example, 
celluloses, hemicelluloses and pectins.54 Hemicelluloses, for instance, are a type of 
heterogeneous polysaccharides composed of glucose, xylose, mannose, and galactose.53,54  
Xylans present a backbone of β-(1-4)-linked xylopyranosyl units.53 Mannans include 
galactomannans, which have a β-(1-4)-linked D-mannose backbone to which is attached a 
single α-D-galactose at the C6 position of D-mannose; glucomannans, which have a random 
distribution of β-(1-4)-linked D-glucose and β-(1-4)-linked D-mannose in the main chain;54 and 
galactoglucomannans with additional side chains of α-D-galactose linked to the mannose 
backbone. Xyloglucans are also reported, which have a common structure of β-(1-4)-linked D-
glucan, and three out of four glucose residues are substituted with α-D-(1-6) xylose.53 Some 
dry powder formulations with these polymers have been proposed for tuberculosis therapy. 
Microparticles of gelatin/ sodium carboxymethyl cellulose,55 chitosan,56 alginate/chitosan,57 
hyaluronic acid,58 chitosan/hydroxypropylmethylcellulose and hydroxypropylcellulose,59 have 
all been proposed to encapsulate antitubercular drugs and claimed an application in inhaled 
tuberculosis therapy. In some cases, spray-drying was the technique used for powder 
production (reference 58 and 59). 
 
1.3.2.1. Locust bean gum 
Locust bean gum (LBG) is a neutral polysaccharide composed of mannose and galactose 
monomers, thus belonging to the category of galactomannans. It is extracted from the crush of 
the endosperm of the seeds of Ceratonia siliqua (carob tree), depicted in Figure 1.9.51 This 
tree is very abundant in the Algarve and Mediterranean regions, North Africa, South America 
and Asia.50   
Carob seeds represent 10% of the weight of the fruit of carob tree. The endosperm of seeds is 
composed of about 80% galactomannan and 20% of proteins (albumin, globulin and glutein) 
and impurities.60 Crude galactomannan can be purified in order to eliminate these 
contaminants, for instance by precipitation with ethanol, methanol or isopropanol, by 
enzymatic and alkaline hydrolysis or by formation of copper or barium complexes. In general, 
whatever the option, the obtained product has a higher mannose/galactose ratio and a 
residual amount of proteins and impurities.50 
LBG structure consists of a  linear  chain  of  a (1-4)–linked β-D- mannopyranosyl  units  with  
(1-6)-linked side chains of α-D-galactose, as represent in figure 1.9.50,51,61  
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Figure 1.9: Locust bean gum: Pod (a), seeds (b), crude powder (c) and chemical structure (d). The 
structure is a linear backbone of (1-4)-β-linked mannose units with single (1-6)-α-D-galactose units 
attached. Adapted from reference 50 and 51.50,51  
 
The ratio of D-galactose to D-mannose differs in the various galactomannans, reflecting 
different substitution pattern of side-chain units. The molecular weight is also different, being 
influenced by the origin and growth conditions of the plant during production, harvesting and 
manufacturing practices, amongst other factors.51 For these reasons, the Mannose and 
galactose (M/G)  ratios of galactomannans are always referred as approximate (3/1 for tara 
gum and 2/1 for guar gum).50 In the literature, specific data indicates for LBG a variation from 
3.1/1 to 4/1. As such, LBG molecular weight is generally described to be approximately 310 
kDa, but different sources refer values ranging from 0.3 to 2.0 million Da.61 
The polymer is reported to have an acceptable shelf-life.51 The physicochemical properties of 
galactomannans are also influenced by the distribution and number of galactose units along 
the mannose backbone. The solubility is strongly influenced by the M/G ratio, due to the fact 
that mannose chains are relatively hydrophobic and galactose units are more hydrophilic. For 
this reason, LBG solubility is limited, forming  aggregates  in  cold  water, as the long 
segments of unsubstituted mannose are likely to undergo aggregation.50 Although it is a 
neutral polymer, solubility and viscosity are described to be slightly affected by pH changes 
within the range of 3-11.51 
For biopharmaceutical and tissue engineering applications, an important issue to assess is the 
in vivo biodegradability and biocompatibility of polymer-based materials. Dey et al. classified 
LBG as biocompatible, bioabsorbable and biodegradable, showing ready excretion of 
degradation products.62 It is non-teratogenic and non-mutagenic according to the Joint Food 
American Organization/WHO Expert Committee on Food Additives held in Geneva, in 
April’75.51  
LBG has been explored in some applications of the pharmaceutical and biomedical sciences. 
In pharmaceutical technology, it has been included in drug delivery systems for different 
applications: mucoadhesive formulations and matrix tablet preparations. Furthermore, different 
administration routes have also been addressed, including the oral, buccal, colonic, ocular and 
topical.51 For example, a commercially available tablet system (TIMERx®) developed by 
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Penwest Pharmaceuticals Company consisting of locust bean gum and xanthan gum displays 
both in vitro and in vivo controlled release potential. Nevertheless, to the best of our 
knowledge, the application of LBG in the context of pulmonary delivery was not proposed 
before, neither was its processing using spray-drying. With its composition based on mannose 
and galactose, LBG is a strong candidate for the formulation of carriers aimed at macrophage 
targeting. 
 
1.3.2.1.1. Locust bean gum as carrier for targeting of alveolar 
macrophages 
Tuberculosis infection occurs principally in respiratory tract due to the propagation of M. 
tuberculosis via inhalation. For this reason, the airways are the main target area for 
antitubercular drugs. Currently, investigators and clinicians argue the replacement of oral and 
intravenous therapies with inhaled antibiotics therapy, due to the fact that this therapy would 
allow higher local drug concentrations and less systemic side effects with the same dose. 
Different approaches are discussed and three strategies can be distinguished: (a) inhaled 
antibiotics can be used for replacement or added-onto oral and intravenous therapy; (b) 
specific targeting of alveolar macrophages; (c) searching for synergistic drug combinations. 
These strategies can be developed and applied in association.12  
Targeted drug delivery of the alveolar macrophages has been considered an attractive 
strategy for the treatment of infectious diseases related with intracellular pathogens, such as 
Mycobacterium  tuberculosis,  Mycobacterium  leprae and Salmonella enterica.6 Specifically, 
M. tuberculosis survives for a long time and can replicate in the phagosomes of the alveolar 
macrophages, and dendritic cells. Therefore, it is important to consider for TB therapy a high 
antibiotic concentration on the alveolar area where infected macrophages reside, along with a 
strategy to specifically target alveolar macrophages.12   
Aerosolizing antitubercular drugs without any carrier may not be adequate to target M. 
tuberculosis residing inside macrophages. Their formulation in delivery systems that can 
simultaneously have an adequate aerodynamic diameter and be phagocytosed by 
macrophages would be the most adequate. Particles with Daer between 0.5 to 2 µm are 
suitable to reach the alveolar zone and those of 1-2 µm have an ideal size for macrophage 
uptake.63 Another advantage is that, after phagocytosis, macrophages may migrate to the 
periphery of lung granulomas leading to increased drug penetration.5 As described above, 
different delivery systems have been engineered to incorporate antibiotics to target 
macrophages. Although targeting macrophages is a promising approach, there are several 
uncertainties and risks that need to be considered, particularly regarding long term 
Locust bean gum-based microparticles for pulmonary delivery of antibiotics | 2015 
 
Master dissertation in Biomedical Sciences | 23  
 
toxicological effects of the used excipients.12 Synthetic microparticles, such as those 
composed by PLGA and PLA, have been tested as carriers of antitubercular drugs. As they 
are insoluble in water, dissolution and systemic absorption will not occur and, therefore, 
macrophage uptake is favoured.63 However, natural polymers might be preferred over 
synthetic ones regarding the matrix composition because of higher propensity for 
biocompatibility and biodegradability, which are expected to provide better long-term 
toxicological profile. 
Several drug carriers, microparticles and nanoparticles, have been produced with modified  
surfaces to exhibit ligands with specific affinity for macrophage surface receptors.64 For 
example, Brandhonneur et al. demonstrated that surface modification by grafting cell-specific 
ligands (agglutinin, RGD and mannose-PEG3-NH2) on PLGA microparticles increased their 
uptake by macrophages.65  
As mentioned before (section 1.1.2), macrophages have unique surface receptors that might 
recognise preferentially several polysaccharide moieties present on the surface of infecting 
organisms, including in the bacterial cell wall.57,64 Phagocytosis-related receptors present on 
macrophage surface are ideal structures for macrophage-targeted therapy.17 One of the 
receptors involved in macrophage surface recognition of materials is the mannose receptor, 
known to recognise not only mannose units, but also fucose, N-acetylglucosamine units and 
sulphated sugars.17,66 For this reason mannose has been described as a functional group that 
can mediate the direct targeting of carriers to macrophages,67 and its use has been 
approached in several works describing the mannosylation of antitubercular drug carriers.6,63  
Benefiting from a similar composition regarding the referred moieties, polysaccharides might 
be good candidates to compose the matrix of drug carriers aimed at macrophage targeting, as 
they can use the same recognition pathways of the infecting organisms.17 Additionally, 
polysaccharides present the advantage of being natural polymers, with the consequent 
propensity for biocompatibility and biodegradability described before. In particular, 
galactomannans having a composition based on mannose and galactose units, are promising 
regarding the described approach, as mannose and galactose units are expected to be 
favourably recognised, respectively,  by mannose receptors and galactose lectin receptors, 
potentiating macrophage uptake.6,17,68 
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2. Objectives 
This proposal is aimed at developing and testing the ability of locust bean gum (LBG) to be 
used as matrix material of microparticles produced by spray-drying, and proposing these as 
carriers for the pulmonary administration of antibiotics. The antibiotics isoniazid and rifabutin 
were selected as model drugs, thus directing the developed formulations to the treatment of 
tuberculosis.  
To accomplish the referred general objective, several partial objectives were considered, 
which are disclosed below: 
1) To optimize the conditions to produce LBG-based microparticles with the particular focus of 
enabling deep lung delivery;  
2) To associate to the microparticles the model antibiotics isoniazid and rifabutin, either 
individually or in association;  
3) To characterize the microparticles regarding their morphology and aerodynamic properties; 
4) To investigate the drug release profile in media relevant for the objective of lung delivery 
and tuberculosis therapy;  
5) To evaluate the cytotoxicity of microparticles in human cell lines that are relevant for the 
application;  
6) To evaluate in vitro the microparticle capacity to induce macrophage activation and capture, 
in two lines of macrophages (human and rat). 
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3. Materials and Methods 
3.1. Preparation of locust bean gum microparticles by spray-drying 
3.1.1. Preparation of polymer dispersions 
Microparticles were designed to have a polysaccharide matrix based on locust bean gum 
(LBG, C30H50O26, molecular weight approx. 310 kDa, Sigma-Aldrich, Germany). To enable the 
formation of a LBG dispersion with adequate viscosity to permit spray-drying, the addition of 
hydrochloric acid (HCl) was required.  
As depicted in figure 3.1 route A, to prepare the dispersions for spray-drying LBG was 
triturated in a glass mortar for 10 minutes, after which 5 mL HCl 0.1 M were slowly added and 
grinding continued. This was followed by the addition of purified water previously heated to 85 
ºC, up to a final volume of 50 mL. The concentration of LBG in the final dispersion was 2% 
(w/v). The dispersion was maintained under magnetic stirring for 30 minutes, and 
subsequently placed on a water bath at 85 ºC under slow stirring for additional 30 minutes. At 
the end, the dispersion was kept under stirring overnight, until the moment of spray-drying. 
Two antitubercular drugs were associated to the microparticles, INH and RFB. These were 
incorporated in the dispersion at different phases, depending on their solubility in water. INH 
(C6H7N3O, molar mass 137.14 g/mol, Sigma-Aldrich, Germany)23,69 is a hydrophilic drug. It was 
first triturated in a porcelain mortar, then weighed in a test tube and solubilised with purified 
water for 10 minutes. Afterwards, the dissolution was slowly added to the LBG polymeric 
dispersion (2%, w/v), formed as indicated above. The LBG.INH dispersion was kept under 
stirring another 90 minutes until spray-drying (Figure 3.1, route A and B). The amount of drug 
incorporated in the formulation corresponded to an LBG.INH mass ratio of 10:1. 
RFB (C46H62N4O11, molar mass 847.00 g/mol, Chemos, Germany)70 is a lipophilic drug and 
was mixed with LBG powder prior to any dissolution. The mixture of the two solid materials 
was performed by geometric dilution, and trituration took place in a glass mortar. After 
grinding, the same procedure used to prepare the LBG dispersion (without drugs) was 
followed (Figure 3.1, route C). RFB was associated to LBG in amounts leading to LBG.RFB 
mass ratios of 10:1, 10:0.5 and 10:0.2.  
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Figure 3.1: Schematic representation of experimental steps involved in the preparation of LBG 
microparticles, unloaded or loaded with antitubercular drugs. A) Method of preparation of LBG 
dispersion is the basis of the process. B) INH was previously triturated and dissolved in water, being 
subsequently added to the LBG or LBG.RFB dispersion for the preparation of formulations LBG.INH 
and LBG.INH.RFB, respectively. C) Rifabutin was added to the LBG powder, and both were triturated. 
Rest of protocol was the same applied for LBG only. INH: Isoniazid, LBG: Locust bean gum; RFB: 
Rifabutin.  
 
When a concomitant association of both drugs was performed, the procedures used for the 
isolated drugs were applied. In summary, RFB was always added at the beginning, 
undergoing grinding with LBG, and INH was first dissolved separately and then added to the 
previously formed dispersion of LBG.RFB (Figure 3.1, route B and C). The formulations of 
drug association reflected the drug amounts of individual formulations: INH was always 
associated at a LBG.INH mass ratio of 10:1, while RFB was associated at both 10:1 and 
10:0.5. Therefore, two formulations of drug association were produced: LBG.INH.RFB = 10:1:1 
and 10:1:0.5.  
 
 
LBG.RFB 
LBG.INH 
LBG.INH.RFB 
Unloaded LBG 
LBG.INH.RFB 
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3.1.2. Spray-drying of polymer/drug dispersions 
Polymeric dispersions (LBG) with or without drugs were spray dried using a Büchi B-290 
laboratory mini spray dryer (Büchi Labortechnik AG, Switzerland) equipped with a high 
performance cyclone. In order to obtain microparticles with adequate aerodynamic and flowing 
properties regarding the objective of lung delivery to reach the alveolar zone, the operating 
parameters were optimized as follows: inlet temperature: 160 ± 2 ºC; aspirator setting: 85%; 
feeding speed: 0.8 ± 0.1 mL/min; and spray flow rate: 473 L/h. These conditions resulted in 
outlet temperature of 102 ± 1 ºC. After spray-drying, the microparticles were collected, placed 
in a dark flask and stored inside a desiccator until further use.  
Mannitol (C6H14O6, mass molecular 182.17 g/mol, Sigma-Aldrich, Germany)71 microparticles 
were also produced to be used as control in certain assays. A solution of 2% (w/v) was 
prepared and spray-dried at inlet temperature: 160 ºC, aspirator setting: 80%; feeding speed: 
1.6 ± 0.1 mL/min; and spray flow rate: 473 L/h. These conditions resulted in outlet temperature 
of 88 ± 1 ºC. After spray-drying, the microparticles were collected, placed in a flask and stored 
inside a desiccator until further use. 
The spray-drying yield was calculated by gravimetry, comparing the total amount of solids 
initially added for the preparation of the spraying dispersions with the final amount of 
microspheres that was collected (n = 3).  
 
3.1.3. Production of fluorescently labelled microparticles 
Certain assays required the use of fluorescent microparticles, such as the determination of 
microparticle uptake. Unloaded fluorescent LBG microparticles were obtained by spray-drying 
in the same conditions described above for unlabelled LBG (the only modification was a slight 
adjustment of acid volume, in this case 1.5 mL for the 50 mL of final volume). The attribution of 
a fluorescent label was provided by fluorescein, which was chemically associated to LBG 
polymeric structure. The setup of the chemical reaction was performed taking into account the 
number of primary nucleophilic groups ("OH") in each LBG monomer, and it was decided to 
label 10% of this structural unit. Figure 3.2 describes the synthesis reaction. At pH 4, 
fluorescein reacted with N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDAC), which donates one “OH” group to fluorescein, resulting in the formation of reactive 
groups in this molecule. These groups will then react with the nucleophilic groups present in 
the structure of LBG, thus allowing the synthesis of a fluorescent polymer. 
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Figure 3.2: Synthesis reaction of fluorescent LBG: N, N-(3-Dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDAC) reacts with fluorescein (green arrows), forming a reactive 
group that will attack the nucleophilic group of LBG structure (indicated in blue). LBG labelled with 
fluorescein is obtained, which is represented by F, this group being surround in yellow.  
 
To initiate the reaction, LBG (1.0 g) was solubilized in HCl at the concentration of 1x10-4 M (pH 
4) in order to obtain a final LBG concentration of 1% (w/v). The dispersion was maintained 
under magnetic stirring for 30 minutes, and subsequently placed on a water bath at 85 ºC, 
under slow stirring, for additional 30 minutes. At the end, the dispersion was kept under stirring 
overnight, until the addition of fluorescein and EDAC.  
Fluorescein (45.5 mg) was solubilised in ethanol 96% (v/v) and added to the previously formed 
LBG dispersion. The added amount of fluorescein was calculated to represent approximately 
2% of number of moles of LBG. EDAC (34.79 mg) was dissolved in milli-Q water, and added 
to the dispersion. This was kept under stirring for 72 hours, protected from light.  
After this time, the dispersion was inserted on a dialysis membrane (Sigma Aldrich, Germany; 
molecular-weight cut off of 2000 Da) in order to eliminate unreacted fluorescein and other 
reaction sub products. In dialysis, a low stirring rate was maintained, and water was changed 
twice a day during one week. When the water became clear, the dialysis was assumed to be 
finished, the suspension was placed in glass petri dishes and placed at -20 ºC. After initial 
freezing, samples were placed at -80 ºC for 3 days and finally lyophilized for 48 hours 
(FreeZone Benchtop Freeze Dry System, LABCONCO, USA). The labelled polymer was 
weighed and stored in a desiccator until further use, under light protection.  
Poly (vinyl alcohol) (PVA) was also labelled for the same purpose, following the same protocol 
described above for LBG. As PVA ([-CH2CHOH-]n, MW 89 - 98 kDa, Sigma-Aldrich, 
Germany)72 has higher amount of nucleophilic groups as compared with LBG, in order to 
maintain the percentage of labelling, a comparison of the number of carbon atoms per 
monomer in PVA and LBG was established. PVA has ¼ of LBG carbons and it was decided to 
label only 0.5% of moles of this polymer.  PVA (1 g) was dissolved in HCl 10-5 M at 1% (w/v). 
This solution was maintained at 80 ºC under stirring overnight, until two hours before adding 
fluorescein and EDAC. Fluorescein (43 mg) was pre-dissolved in ethanol 96% (v/v), EDAC (33 
mg) was pre-dissolved in water and both were then added to the solution. This was kept under 
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stirring for 72 hours under light protection. After this time, the solution was transferred to a 
dialysis membrane, and was kept in dialysis for one week. As in LBG, the solution was frozen 
at -20 ºC, then placed under -80 ºC, and lyophilised for 48 hours. After this procedure, the 
recovered polymer was weighed and stored in a desiccator until further use, ensuring light 
protection. 
PVA was grinded in a mortar and then dissolved in water, being kept under stirring at 80 ºC 
until complete dissolution (2 hours). Before spray drying fluorescently labelled PVA (2%, w/v), 
spray-drying parameters were optimised. The selected parameters were: inlet temperature: 
155 ± 2 ºC; aspirator setting: 80%; feeding speed: 1.07 mL/min; and spray flow rate: 473 L/h. 
These conditions resulted in outlet temperature of 96 ± 2 ºC. The fluorescent PVA 
microparticles were collected and stored in desiccator, protected from light, until further use.  
 
3.2. Characterisation of microparticles 
The surface morphology of produced microparticles was characterised by field emission 
scanning electron microscopy (FESEM; FESEM Ultra Plus, Zeiss, Germany). Dry powders 
were placed onto metal plates and 5 nm thick iridium film was sputter-coated (model Q150T 
S/E/ES, Quorum Technologies, UK) on the samples before viewing.  
Microparticle size was estimated as the Feret’s diameter (distance between two tangents on 
opposite sides of a microparticle) and was directly determined by optical microscopy 
(Microscope TR 500, VWR international, Belgium) from the manual measurement of 300 
microparticles (n = 3). 
Real density was determined using a Helium Pycnometer (Micromeritics AccuPyc 1330, 
Germany). Briefly, the sample was previously weighed in a sample holder of known volume 
that was then placed in the equipment chamber, which was sealed for measurements. Helium 
was then inserted in the chamber under vacuum, in order to occupy its entire volume. It has 
the capacity to fill pores and spaces between microparticles. The sample volume was then 
determined by the difference between the chamber volume and the volume of helium.73 Real 
density (g/cm3) was obtained by dividing the sample weight by its volume.  
Bulk and tap densities (g/cm3) were determined using a tap density tester (Densipro 250410, 
Deyman, Spain), and consisted on the volume measurement of a known weight of powder 
before and after tapping, respectively (n = 3). The determination of tap density involved 
tapping the sample until no further reduction of powder volume was observed (which 
corresponded to an average of 180 taps). The Carr Index (%) was estimated as a theoretical 
parameter to evaluate the flow properties of microparticles30,59 and was calculated, as follows:  
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Where Tap is tap density (g/cm3) and Bulk is bulk density (g/cm3).  
The aerodynamic diameter (Daer) was determined theoretically and is defined as the diameter 
of a sphere of unit density that has the same terminal settling velocity as the particle under 
consideration. It was calculated based on the following equation:  
    (30) 
Where s = 1 g/cm3, Dg corresponds to geometric diameter (determined as the Feret’s 
diameter (µm)), Real is the real density of microparticles in the same unit as s (g/cm3), and  
is the dynamic shape factor of the particle.30,74 Regarding the latter, considering that the shape 
of microparticles is identic to the pollen-shaped described by Hassan et al.,  was assumed to 
be 1.2.30,75  
 
3.3. Determination of drug association 
Determination of drug content in microspheres was performed by UV-Vis spectrophotometry. 
This technique permits relating absorbance of radiation at a specific wavelength with the 
concentration of the dissolved drug. The Lambert-Beer law expresses that absorbance of a 
solution is proportional to the solute´s concentration: 
 (31) 
Where A is absorbance at specific wavelength,  is the wavelength-dependent molar 
absorptivity coefficient (M-1 cm-1), c is solute concentration (M) and l is the path length (cm).76 
The specific wavelength () to determine each drug was defined by doing a screening. For 
INH, the absorbance maximum was obtained at 265.5 nm, while for RFB the maximum was 
registered at 240 and 500 nm. The absorbance maximum of two drugs in solution is 268.5 nm. 
This value corresponds to the intersection between the spectrums of two drugs, as described 
in figure 3.3. The wavelength used for determination of INH in formulation LBG.INH was 265.5 
nm, and RFB in formulation LBG.RFB was 500 nm. A screening of the matrix material (LBG) 
revealed no interference at the selected wavelengths.  
Different conditions were, however, required for drug quantification in formulations having drug 
association, because RFB has absorbance at two regions, near the region of INH 
(30) 
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quantification and also in the visible region. For formulation with both encapsulated drugs, 
LBG.INH.RFB, a quantification at the wavelength of 268.5 nm was performed. 
 
Figure 3.3: Isoniazid and Rifabutin Spectra. INH drug at 50 µg/mL and RFB at 175 µg/mL solubilised 
in HCl 0.1 M. 268.5 nm was determined experimentally as a point of intersection of the spectrum of both 
drugs.  
 
At this particular wavelength, the measured absorbance is equal to the sum of INH and RFB 
absorbances, as described in the next equation: 
For  = 268.5 nm, 
   (Equation 1) 
To enable the determination of the concentration of each drug in MPs, it was established that 
ARFB was measured at 500 nm, and determination of real content of RFB in the sample was 
performed by linear regression from equation 2. At that wavelength, INH does not have 
significant absorbance, as shown in figure 3.3.  
For  = 500 nm, 
  (Equation 2) 
After this determination, the absorbance of the sample could be measured at 268.5 nm. In this 
case it was necessary to dilute the sample until appropriate concentration. Then equation 1 
becomes: 
For  = 268.5 nm, 
  (Equation 3) 
268.5 
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With the value of RFB concentration quantified at 500 nm, it was possible to determine the 
value of its absorbance at 268.5 nm. The quantification of INH was also performed at 268.5 
nm. To determine the final and real amount of INH, the contribution of RFB at that wavelength 
had to be subtracted. 
 
 (Equation 4) 
    (Equation 5) 
 
In order to determine microparticle drug content, a determined amount of drug-loaded 
microparticles was incubated with HCl 0.1 M, under magnetic stirring for 60 min. The specific 
conditions of the assay are described in table 3.1. Samples were then centrifuged (8000 rpm, 
30 min; 5810 R, Eppendorf, Germany) and filtered (0.45 µm), before quantification by UV-Vis 
spectrophotometry (Pharmaspec UV-1700, Shimadazu, Japan).  
For all formulations (LBG.INH, LBG.RFB and LBG.INH.RFB), a calibration curve of the 
corresponding drug was performed in a solution obtained from the solubilisation of LBG 
unloaded microparticles in HCl 0.1 M. 
 
Table 3.1. Assay conditions for determination of drug association efficiency and loading 
capacity.  
Formulations Drugs 
Wavelength 
(nm) used for 
determination 
The wavelength-
dependent molar 
absorptivity 
coefficient (M-1 
cm-1) 
R-
squared  
MPs 
Weight 
(mg) 
Volume 
of HCl 
0.1 M 
(mL) 
LBG.INH Isoniazid 265.5 0.036 0.998 1.5 10 
LBG.RFB Rifabutin 500 0.003 0.999 15 10 
LBG.INH.RFB 
Isoniazid 268.5 0.036 0.997 
15 10 
Rifabutin 500 and 268.5 0.003 and 0.030 0.998 
INH: Isoniazid; LBG: Locust Bean Gum; RFB: Rifabutin. 
 
The estimation of drug association efficiency (AE) and microparticle loading capacity (LC) was 
performed as follows (n = 3): 
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3.4. In vitro drug release 
The determination of drug release was performed for the formulations LBG.INH = 10:1, and 
LBG.INH.RFB = 10:1:0.5 (w/w). The assays were conducted in a medium simulating the pH of 
the alveolar zone, PBS pH 7.4 (PBS tablets, Sigma-Aldrich, Germany), and also in a medium 
resembling the pH of macrophage phagolysosome, citrate buffer pH 5 (Sigma-Aldrich, 
Germany). For microparticles containing RFB, the medium was added of 1% (v/v) Tween 80 
(Sigma-Aldrich, Germany) to facilitate drug dissolution and subsequent quantification. In order 
to establish the experimental setup, it was necessary to determine the solubility of RFB in the 
specific media. One of the requirements of this in vitro assay is maintaining sink conditions.77 
In experimental conditions, the RFB concentration in release medium was always less than 
30% of its maximum solubility (0.496 mg/mL, determined experimentally). This is in 
accordance with the advised by the European Medicines Agency77 and, therefore, it is 
considered that the assay was performed under sink conditions.   
A determined amount of microparticles (of each formulation) were incubated with the 
respective media, under mild shaking (100 rpm, orbital shaker OS 20, Biosan, Latvia) at 37 °C. 
The released drug was quantified at predetermined times by collecting a sample (1 mL) and 
performing a quantification by UV-Vis spectrophotometry, using the calculations explained 
above for drug association. Sample dilutions were applied whenever needed. For each 
formulation a different calibration curve was used, consisting of a solution obtained from the 
incubation of unloaded LBG microparticles with the corresponding medium and assay 
conditions (microparticle concentration and duration of assay), followed by centrifugation 
(8000 rpm, 60 min) and filtration (0.45 μm). Specifically, for LBG.INH, 10 mg of microparticles 
were incubated in 12 mL of each release media in test tubes. At specific time intervals (5, 10, 
15, 20, 30, 60, 90, 120, 240, 360 and 1440 minutes), samples were collected individually, 
filtered (0.45 µm), appropriately diluted (1:3) and the absorbance determined (n = 3). 
For LBG.INH.RFB, 20 mg of microparticles were suspended in 10 mL of release medium (PBS 
plus 1% Tween 80®) and incubated. At specific time intervals (10, 20, 30, 60, 90, 120, 180 and 
240 minutes), the samples were collected, centrifuged (16 000 x g, 15 minutes, Heraeus 
Fresco 17 Centrifuge, Thermoscientific, United States of America), filtered (0.45 µm), and the 
absorbance of RFB quantified at 500 nm. Following, the samples were diluted 1:10 and the 
total absorbance quantified at 268.5 nm (n = 3).  
 
3.5. Powder crystallinity 
The crystal structure of raw material (LBG), drugs and formulations was evaluated by Powder 
X-ray diffraction (PXRD). The samples were anaylsed in a PANalitycal X’Pert Pro 
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diffractometer, using nickel filtered CuKα radiation with a wavelength of 0.154 nm. An 
X'Celerator detector was used and the operating conditions were 45 kV and 35 mA. The 
diffractograms were obtained in reflection mode from 5 to 70 ° 2theta with a step size of 0.05 ° 
and 1500 s per point. 
 
3.6. Cell culture 
3.6.1. A549 cell line: Human alveolar epithelial cells 
The  A549  cell  line  was  obtained  from  the  American  Type  Culture  Collection (ATCC, 
catalog number 185™, Rockville, USA). It derives from human lung adenocarcinoma and the 
cells form confluent monolayers characteristic of type II alveolar epithelium.78  
Cell cultures were grown in 75 cm2 tissue culture flasks (Orange Scientific, Belgium) inside an 
incubator having humidified 5% CO2/95% atmospheric air at 37 ºC (HerAcell 150, Heraeus, 
Germany). Cell culture medium (CCM) was Dulbecco’s Modified Eagle Medium (DMEM, 
Sigma-Aldrich, Germany), supplemented with 10% (v/v) Foetal Bovine Serum (FBS, Gibco, 
Life Technologies, USA), 1% (v/v) L-glutamine solution (Sigma-Aldrich, Germany), 1% (v/v) 
non-essential amino acids solution (Sigma-Aldrich, Germany) and 1% (v/v) 
penicillin/streptomycin (Sigma-Aldrich, Germany). The medium was exchanged twice a week 
and cells were sub-cultured weekly. Subculturing was initiated by rinsing the cell layer with 
PBS followed to 4-5 minutes exposure to trypsin-EDTA (Sigma-Aldrich, Germany). The cells 
were then re-suspended in new medium before and after centrifugation (1500  g, 1 minute, 
room temperature, Centrifuge MPW – 223e, MedInstruments, Poland), and  sub-cultivated at 
1/8 ratio. Cells were used from passage 27 to 65.  
 
3.6.2. THP-1 cell line: Human leukemic monocytes 
THP-1 cell line is an acute monocytic leukemic cell line and was obtained from the Leibniz-
Instituit DSMZ. THP-1 cells were grown in suspension in 25 cm2 or 75 cm2  tissue culture 
flasks (Greiner Bio-one, Germany) in RPMI 1640 medium (Lonza Group AG, Switzerland) 
supplemented with 10% (v/v) FBS, 1% (v/v) L-glutamine and 1% (v/v) penicillin/streptomycin. 
Cells were maintained at 37 °C in a 5% CO2/95% air humidified atmosphere. The cell culture 
was maintained between 0.2 x106 and 0.8 x 106 cells/mL. When reaching this concentration, 
cells were centrifuged (1500  g, 2 minutes, room temperature, centrifuge MPW – 223e, 
MedInstruments, Poland), re-suspended in fresh medium and, after determination of the 
accurate cellular density, re-suspended in new passage at the concentration of 0.2 x10 6 
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cells/mL. Sub cultivation was performed two/three times a week and cells were used from 
passage 10 to 20 after thawing. 
 
3.6.2.1. Differentiation of THP-1 cells into macrophage-like cells 
Differentiation of THP-1 monocytes to provide the macrophage phenotype was performed 
using phorbol 12-myristate 13-acetate (PMA, C36H56O8, Sigma-Aldrich, Germany).79 An 
optimisation of conditions (PMA concentration, time of exposure) was performed to determine 
those permitting the adequate adhering phenotype, typical of macrophage populations in 
vitro.35,80 THP-1 cells at density of 0.2 x 106 cells/mL were suspended in 5 mL of RPMI medium 
supplemented with 50 nM PMA and seeded (1.0 x 106 cells per well),  in 6-well plates (9.60 
cm2, Greiner Bio-one, Germany). Cells were exposed to PMA for 48 hours, after which the 
medium was replaced by fresh medium without PMA for another 24 hours before the 
experiments. All experiments were performed in macrophage-like THP-1 cells. Different 
assays required the use of different plates, thus requiring an optimisation of differentiation 
procedures.  
For assays in 6-well plates, THP-1 cells at density of 0.2 x 106 cells/mL were re-suspended in 
medium supplemented with 50 nM PMA, and seeded in 5 mL final volume of cell suspension. 
After 48 hours, medium was replaced by 2.5 mL of fresh medium. In 12-well plates (3.85 cm2, 
Orange Scientific, Belgium) a final volume of 2 mL cell suspension at 0.2 x 106 cells/mL (with 
PMA) was used. After 48 hours, 1 mL of fresh medium was used to replace the medium. In 96-
well plates (0.33 cm2, Orange Scientific, Belgium), seeding density was 0.035 x 106 cells per 
well with 100 µL of RPMI previously supplemented with 50 nM of PMA. The cells were 
incubated for 48 hours in incubator. After, the medium was replaced by 100 µL fresh medium 
and incubated for 24 hours before experiments. Optimal cell seeding density for these plates 
was confirmed in preliminary experiments through cell growth curves. 
 An efficient differentiation was demonstrated by an immunocytochemistry assay. After the 
application of the differentiation protocol, macrophages were washed twice with 5 mL of a 
solution consisting of a cold mixture of 3% (v/v) FBS in PBS pH 7.4. This solution will be 
denominated in rest of text by PBS.3%FBS.  Cells were harvested by scraping, suspended in 
PBS.3%FBS and centrifuged (1500  g, 2 minutes, room temperature, centrifuge MPW – 
223e, MedInstruments, Poland) twice. After that, macrophages were placed in a 6-well plate 
(1.0 x 106 cells/well) and incubated with a solution of PBS.3%FBS containing the monoclonal 
antibody anti-CD11b (BioLegend Inc, USA) for 1 hour at 4 ºC, in a dark box. After that period, 
cells were washed twice with PBS.3%FBS, centrifuged and re-suspended with this solution 
prior to the analysis by flow cytometry (FacScalibur Cell Analyzer, BD Biosciences, Belgium).   
Locust bean gum-based microparticles for pulmonary delivery of antibiotics | 2015 
 
Master dissertation in Biomedical Sciences | 36  
 
3.6.3. Cell line NR8383: Rat alveolar macrophages 
The cell line NR8383 was purchased from ATCC (catalog number CRL-2192TM), 
corresponding to rat alveolar macrophages collected by lung lavage of Rattus norvegicus.81  
NR8383 cells grow in mixed culture, half the population keeps adherent and half suspended. 
The used CCM consisted of Ham’s F12 (Lonza, Group AG, Switzerland) supplemented with 
15% (v/v) FBS, 1% (v/v) L-Glutamine and 1% (v/v) penicillin/streptomycin. Cells were 
maintained at 37 °C in a 5% CO2/95% air humidified atmosphere on 75 cm2 flasks (Orange 
Scientific, Belgium). The culture was maintained by transferring suspending cells to a new 
flask, where about one half of the cells will re-adhere. To do so, suspending cells were placed 
in a falcon, centrifuged, and re-suspended in fresh medium. The medium was exchanged 
three times/week and the suspending cells were eliminated together with medium. Adherent 
cells were those used to perform the assays described below and their harvesting was made 
by scraping. 
 
3.7. Cytotoxic evaluation 
The cytotoxic evaluation of the diverse microparticle formulations developed in this work was 
performed in vitro by means of two different assays. The 3-[4, 5-dimethylthiazol-2-yl]-3,5 
biphenyl tetrazolium bromide (MTT, Sigma-Aldrich, Germany) test, which will be simply 
referred to as MTT assay, is a metabolic assay that provides information on the effect of 
contact with formulations on the mitochondrial activity of cells. In this assay, yellow tetrazolium 
salts of MTT are reduced by the action of dehydrogenase enzymes present in mitochondria of 
viable cells, resulting in the formation of purple formazan that accumulates intracellularly, as 
described in figure 3.4. Formazan crystals are then dissolved with appropriate organic solvents 
and quantified by spectrophotometric analysis. The absorbance of purple formazan is directly 
proportional to the quantity of viable cells. 
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Figure 3.4: Cytotoxicity assays: After exposure of microparticles, metabolic activity of viable cells can 
be determined using 3-[4, 5-dimethylthiazol-2-yl]-3,5 biphenyl tetrazolium bromide (MTT) test, which 
consists in the reduction of the tetrazolium salt to formazan by cellular dehydrogenases. The presence 
of lactate dehydrogenase (LDH) enzyme in cell culture medium is indicator of damaged cells. Released 
LDH is measured with a coupled enzymatic reaction that results in the conversion of a tetrazolium salt 
(iodonitrotetrazolium) into a red color formazan by diaphorase. EM: Electron mediator; HCl: hydrochloric 
acid NAD/NADH: cofactor nicotinamide adenine dinucleotide. 
 
The second assay consisted in the quantification of lactate dehydrogenase (LDH) released by 
cells upon contact with formulations. As LDH is a cytosolic enzyme, its release implies the 
disruption of the cell membrane and, thus, this assay provides data on cytotoxicity based on 
the evaluation of cell membrane integrity. Using an appropriate toxicity assay kit (commercial 
kit, Sigma-Aldrich, Germany), LDH released from cells to the culture medium will convert 
lactate to pyruvate via reduction of the co-factor nicotinamide adenine dinucleotide (NAD+ to 
NADH). The enzymatic reaction is then stopped with HCl 1 M, and diaphorase also present in 
the reagent uses NADH to reduce a tetrazolium salt (dye solution) to red formazan product, as 
described in figure 3.4. The amount of formazan is quantified spectrophotometrically and is 
directly proportional to the amount of released LDH present in the medium. 
 
 
Lung Cells 
Alveolar macrophages 
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3.7.1. MTT assay 
The MTT assay was performed on A549 and macrophage-derived THP-1 cells. Optimal cell 
seeding density was confirmed in preliminary experiments for two cell lines. A549 cells were 
seeded at a density of 1 x 105 cells/well on 96-well plates (Orange Scientific, Belgium), in 100 
µL of complete DMEM. Cells were incubated for 24 hours at 37 ºC in 5% CO2 atmosphere 
before use. A549 cells were exposed to the microparticles in suspension in cell culture 
medium without FBS. THP-1 cells were differentiated into macrophages before the 
experiments, according to previously described procedures. With these cells, the assay was 
performed either exposing the microparticles as a suspension in cell culture medium (RPMI 
without FBS) or as a dry powder. When the formulations were exposed as suspension, the 
assay was performed in 96-well plates (cell density of 0.035 x 106 cells per well), while 12-well 
plates (cell density of 0.40 x 106 cells per well) and six-well plate (1x 106 cells per well) were 
used when aerosolisation of dry powder was performed. 
 
3.7.1.1. Samples presented in solution/suspension 
The in vitro cytotoxicity of individual drugs, raw material (polymer) and microparticle 
formulations was tested in A549 and macrophage-derived THP-1 cells in the form of a 
solution/suspension prepared in cell culture medium. Assuming that drugs represent a 
maximum of 10% of the amount of polymer in each formulation, INH and RFB were tested 
individually at the concentrations of 0.01, 0.05 and 0.1 mg/mL. In turn, the matrix polymer as 
obtained commercially (LBG), unloaded LBG MPs and drug-loaded MPs (LBG.INH 10:1; 
LBG.RFB 10:1, 10:0.5, 10:0.2 and LBG.INH.RFB 1:1:1 and 1:1:0.5) were evaluated at the 
concentrations of 0.1, 0.5 and 1.0 mg/mL. Cell culture medium and sodium dodecyl sulphate 
(SDS, Sigma-Aldrich, Germany) at 2% (w/v) were used as negative and positive control of cell 
death, respectively. All test substances were solubilised/dispersed in pre-warmed CCM 
without FBS, and exposed to both cell lines for 3 and 24 hours.  
Due to the hydrophobic character of RFB, it does not dissolve directly in CCM and, therefore, it 
was solubilised in dimethyl sulfoxide (DMSO, Sigma-Aldrich) at a drug concentration of 20 
mg/mL, being subsequently diluted to the desired concentrations with CCM. Consequently, 
DMSO was at a concentration of 0.5% (v/v) in RFB solutions tested in cells. The effect of 
DMSO on cell viability (diluted in CCM) was determined as control, in concentrations varying 
between 0.0313% and 2% (v/v).  
When A549 cells were used, solutions/suspensions were removed after the exposure time and 
MTT solution (0.5 mg/mL in PBS pH 7.4) was added. After 2 hours, any formazan crystals 
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generated were solubilised with DMSO and the absorbance measured by spectrophotometry 
(Infinite M200, Tecan, Austria) at 540 nm (background correction at 640 nm). For 
macrophage-like THP-1 cells, the MTT solution was added directly without removing test 
substances. After 2 hours in 96-well plates, for this assay, or 3 hours in 12-well plates and 6-
well plates, when this assay was performed with microparticles aerosolised (next section), a 
surfactant solution comprising 10% of SDS in a 1:1 mixture of dimethylformamide (DMF, 
Sigma-Aldrich, Germany): water was used to solubilise the formed formazan crystals. Plates 
were incubated at 37 ºC for 60 minutes (30 minutes in orbital shaker (150 rpm) and other 30 
minutes at rest to maximize crystal solubilisation). Afterwards, absorbance was read by 
spectrophotometry (Infinite M200, Tecan, Austria) at 570 nm (background correction at 650 
nm). 
Relative cell viability (%) was calculated by the formula:   
 
where A represents absorbance of test substances, S that obtained for 2% SDS and CM that 
of culture medium. The viability of untreated cells (CM) was assumed to correspond to 100% 
of the cell viability, and viability of treated cells was compared to this control. The assay was 
replicated at least three times, each with six replicates.  
 
3.7.1.2. Samples presented by aerolisation 
From the total set of formulations that were developed, four were selected to undergo a 
preliminary assessment of cell viability upon exposure to differentiated THP-1 cells in the form 
of a dry powder. These formulations were unloaded LBG MPs, LBG.INH 10:1, LBG.RFB 
10:0.5 and LBG.RFB.INH 10:1:0.5.  
The formulations were exposed to cells seeded in 12-well plates at a dose of 303 µg/cm2, 
which reflects the conversion of 1 mg/mL (used 96-well plates) to the area of the 12-well plate 
used in the assay. Samples were aerosolized using a Dry Powder Insufflator™ (Model DP-4, 
Penn-Century, USA), which is shown in figure 3.5, and their effect evaluated upon 24 hours 
exposure. Cells were in contact with the samples for two hours without CCM in order to 
simulate the alveolar environment. After this time, 500 µL of CCM were applied in each well, to 
not compromise cell viability due to dryness. A control was performed leaving cells without 
medium for 2 hours, after which the same volume of CCM was added to the wells. The assay 
was also performed at a dose of 50 µg/cm2, which is the minimum dose of formulation that can 
be weighed. This dose was only tested for unloaded LBG MPs and LBG.INH.RFB 10:1:0.5. 
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For this specific approach, cells were seeded in 6-well plates (9.60 cm2) and exposed to the 
microparticles for 2 hours in absence of CCM. After, 1350 µL CCM were added to each well 
until 24 hours of microparticle exposure. A control in the same conditions was performed, in 
absence of microparticles. 
 
Figure 3.5:  Dry powder insufflator: Scheme of sample chamber and air handler (top of sample 
chamber). Adapted from reference 79.82 
 
The insufflator is a device designed for powder administration to animals and allows the 
loading of 1-5 mg of powder.82 The appropriate volume of insufflated air had to be optimised 
for each tested dose and each formulation, as it influences the amount of microparticles 
released from the device. An average of 24 replicates was performed for each formulation 
during the optimisation phase. For the formulation of unloaded LBG MPs and LBG.INH 10:1 
(303 μg/cm2), the average of released dose from device was 52.26 ± 5.2%, while for LBG.RFB 
10:0.5 and  LBG.INH.RFB 10:1:0.5 was 60.71 ± 3.2%. Regarding the lower dose (50 μg/cm2) 
is concerned, unloaded LBG MPs released 43.13 ± 4.73%, while LBG.INH.RFB 10:1:0.5 
released 48.44 ± 4.30%.  
Cell viability (%) was calculated with the formula mentioned above, with slight modifications, 
as no positive control of cell death was used: 
 
Where A represents absorbance of test substance and CM that of culture medium. The 
viability of unexposed cells (CM) was assumed to correspond to 100% of the cell viability, and 
viability of treated cells was compared to this control. The assay was replicated at least three 
times. 
 
  
 
Locust bean gum-based microparticles for pulmonary delivery of antibiotics | 2015 
 
Master dissertation in Biomedical Sciences | 41  
 
3.7.1.3. Determination of Rifabutin IC50 
As formulations containing RFB registered strong cell viability decreases, the concentration 
that inhibits cell proliferation/population on 50% (IC50) of this drug was determined. Serial 
dilutions of RFB in DMSO (0.5% v/v) were prepared (0.00156 to 0.4 mg/mL) and applied on 
differentiated THP-1 cells and A549 cells. After 24 hours exposure, cell viability was 
determined using the same positive and negative controls referred above for the assessment 
of drug solutions.  
For determination the IC50 was used the Standard curve analysis based on a four-parameter 
logistic in SigmaPlot software (version 13.0). 
 
3.7.2. LDH assay 
The determination of LDH release was performed in both A549 and differentiated THP-1 cells 
upon 24 hour exposure to drugs, polymer (LBG) and microparticle formulations. Specifically, 
tested formulations corresponded to unloaded LBG MPs, LBG.INH 10:1, LBG.RFB 10:1, 
10:0.5 and 10:0.2, and LBG.INH.RFB 10:1:1 and 1:1:0.5. 
All formulations/test samples were applied over the cells in the form of solutions/suspensions, 
at the concentration of 1 mg/mL, the maximum concentration used in the MTT assay. 
However, the concentration of 0.5 mg/mL was also tested for RFB as free drug and 
formulations containing this drug. Cells were cultured in 96-well plates in the conditions 
described before for the MTT assay (the assays were in fact performed simultaneously). Upon 
exposure, cell culture supernatants were collected (MTT uses the proper cells, while this 
assay uses the supernatants), centrifuged (16 000 x g, 5 minutes, 4 ºC) and processed using 
a commercial LDH assay kit (Sigma-Aldrich, Germany). Briefly, supernatants were incubated 
with the reaction mixture for 20 minutes and after this time the enzymatic reaction was stopped 
with HCl 1 M (Sigma-Aldrich, Germany). Absorbance was measured by spectrophotometry 
(Infinite M200, Tecan, Austria) at a wavelength of 490 nm (background correction at 690 nm).  
A negative control of LDH release was performed incubating cells with CCM only. The amount 
of LDH released in this case was considered 100%. A positive control of LDH release was 
provided by a lysis solution, provided in the kit. Released LDH (%) upon incubation with each 
sample was determined by comparison with the 100% of the negative control. All 
measurements were performed in triplicate.  
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3.8. Evaluation of macrophage ability to uptake LBG microparticles 
THP-1 cells were differentiated as described in section 3.6.2.1. THP-1 cells at concentration 
0.2x 106 cells/mL were suspended in RPMI medium supplemented with 50 nM PMA and 
seeded in 5 mL/well in 6-well plates for cells in suspension (Greiner Bio-one, Germany). For 
NR8383 cells, those adhered to the flasks were removed with a scraper, suspended in Ham’s 
F12, centrifuged and counted. They were seeded at a density of 1.0 x 106 cells per well in 6-
well plates for adhered cells (Orange Scientific, Belgium), with 2 mL of medium. This 
procedure was performed 24 hours before the test to ensure that 50 to 75% of the original 
population adheres to the well surface. 
The evaluation of microparticle uptake by macrophages was performed by flow cytometry, 
which required the exposure to fluorescently-labelled LBG and PVA microparticles (described 
in section 3.1.3). The assay was performed testing two doses of microparticles: 250 and 50 
µg/cm2. The higher dose was only tested for LBG microparticles and THP-1 cells and implied 
weighing approximately 3.5 mg of dry powder. In turn, the lower dose corresponded to 
approximately 1 mg and was tested in differentiated THP-1 cells and NR8383 cells, for both 
LBG and PVA microparticles).  
Fluorescently-labelled microparticles were aerosolized onto the macrophage layer using a Dry 
powder Insufflator™ (Model DP-4, Penn-CenturyTM, USA), as described in section 3.7. 1.2. 
Optimisation of insufflation using this device was performed for both formulations. In each 
assay, a negative control was used consisting of cells not exposed to microparticles but 
maintaining the same assay conditions.  
After weighing the samples and having the insufflator ready to operate, culture medium was 
removed and microparticles insufflated over the monolayer of macrophages. The incubation 
was allowed for 2 hours at 37 ºC, without CCM. After that time, the phagocytic process was 
finished by the addition of a cold solution of PBS.3% FBS (5 mL, two applications). Cells were 
then scraped and centrifuged (1500 rpm, 2 minutes, room temperature, centrifuge MPW – 
223e, MedInstruments, Poland) in 2 mL of PBS.3% FBS. Afterwards were again re-suspended 
twice in 5 mL of PBS.3% FBS and centrifuged (1500 rpm, 2 minutes, room temperature). The 
cells were finally re-suspended in 1 mL of PBS.3% FBS, transferred for cytometry tubes (BD 
Biosciences, Belgium) and maintained at 4 ºC until the analysis.  
The occurrence of phagocytosis was determined by flow cytometry (FacScalibur cell analyser, 
BD Biosciences, Belgium). In the system, FSC-H/SSC-H channels were used to measure size 
(FSC-H) and granularity of the cells (SSC-H) and side scatter light was used to identify cell 
viable population. Gate 1 was defined with results from the two channels for unexposed cells. 
Region R was defined from the value of fluorescence intensity which is independent on cellular 
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autofluorescence and also on fluorescent molecule in FL-1 channel (blue laser; excitation 488, 
emission 530/30). The amount of cells having fluorescence was considered to have 
phagocytosed microparticles. The assay for each cell line, doses, microparticle formulations 
and controls was replicated at least three times.  
 
3.9. Evaluation of microparticle capacity to activate macrophages  
The capacity of LBG microparticles or unformulated LBG to activate macrophages was tested 
by measuring, upon incubation with macrophage-differentiated THP-1 cells, the release of the 
activation markers tumour necrosis factor-α (TNF-α) and interleukin-8 (IL-8).  
THP-1 cells were seeded on 96-well plates (0.035 x 106 cells/well, 50 nM PMA, 0.1 mL) and 
differentiated as described in section 3.6.2.1. After that, cells were exposed to a solution of 
LBG and to a dispersion of LBG.INH.RFB 10:1:0.5 microparticles at dose 303 µg/cm2 for 24 
hours. The exposure to lipopolysaccharide (LPS, 10 µg/mL)35 was used as positive control and 
cells incubated with CCM, mannitol microparticles or unformulated mannitol were used as 
negative control. The unformulated LBG solution, LBG microparticles and controls were 
prepared with pre-warmed CCM without FBS immediately before application to the cells. After 
24 hours of exposure, cell supernants were collected and centrifuged (10 minutes, 16.000 x g, 
4 ºC, Centrifuge 5804R, Eppendorf, Germany). The levels of IL-8 and TNF-α present in 
supernatants of macrophages were determined by quantitative enzyme-linked immunosorbent 
assay (ELISA) using  human IL-8 and TNF-α ELISA Kits (Invitrogen Corporation, Camarillo, 
USA), according to the manufacturer’s instructions.  
The supernatants were appropriately diluted for IL-8 (approximately 2 times for LBG solution 
and microparticles, and 10 times for LPS). The assay was performed on two occasions with 
two replicates for test substance in each assay. The concentration of individual cytokines for 
each test substance is expressed as percentage of spontaneous release by cells not exposed 
any substance but presenting a basal level of these cytokines.   
 
3.10. Statistical analysis 
The student t-test and the one-way analysis of variance (ANOVA) with the pairwise multiple 
comparison procedures (Holm-Sidak method) were performed to compare two or multiple 
groups. For the analysis of results of in vitro release assay, a two-way ANOVA with 
Bonferroni’s method for multiple comparison test was used. All analysis were run using the 
GraphPad Prism (version 6.07) and differences were considered to be significant at a level of 
p < 0.05. 
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4. Results and Discussion 
The development of antitubercular formulations to be directly delivered to the lungs by 
inhalation is considered a promising approach, as described in the introduction. Antitubercular 
drugs are usually administered orally, in prolonged treatments associated with severe side-
effects, which may lead to reduced patient compliance and may increase the emergence of 
drug-resistant strains. Antitubercular therapy thus needs a critical change.102 The search for 
new antitubercular drugs is of key importance but is not the unique option, as the development 
of new drug delivery strategies may also play an important role. Delivery of antibiotics via the 
pulmonary route has been used for the treatment of pulmonary infections, especially in 
complications of cystic fibrosis, but this route is now becoming increasingly interesting for 
other infectious diseases, including tuberculosis. This approach offers multiple advantages 
over oral delivery, as it enables site-specific drug deposition at high concentrations and 
favorable lung-to-plasma ratio,12,33 provides the possibility of reducing administration doses 
and frequency, and might shorten treatment periods. This would improve efficacy of the 
treatment, reduce drug related toxicity and certainly improve patient compliance.  
This constituted the major motivation of this project. The main goal was the development of a 
new delivery strategy, through the use of inhalable microparticles as carriers of two first-line 
antitubercular drugs (isoniazid and rifabutin). Specifically for these drugs, which present 
severe hepatic and other systemic side effects, the administration by pulmonary route for local 
action would be advantageous.23,70 It is important to indicate that these drugs were considered 
as models, and other antibiotics could potentially be tested and loaded for the treatment of this 
or other lung infections, such as for example pneumonia. 
 
4.1. Preparation of locust bean gum microparticles by spray-drying 
Obtaining a LBG dispersion that permitted spray-drying required great optimisation of each 
step, mainly due to the high viscosity of the polysaccharide. The thickening capacity of LBG is 
reported to depend on factors such as the particle size, solubilisation methods, polymer 
concentration, shear rate and molecular weight distribution.61 LBG at a solid concentration of 
2% (w/v) forms suspensions with too high viscosity to enable spray drying. At 1% (w/v) the 
viscosity is reported to be 2100 - 3750 cps,83 which is much greater than the ideal for an 
operation with the spray-drying equipment (300 cps).48 The literature reports that the 
rheological properties of LBG dispersion can be modified with the change of pH, addition of 
salts, and/or heating.84 In this work, both the reduction of pH and the use of temperature were 
tested. Regarding the use of hydrochloric acid, it was found that a volume of 5 mL HCl 0.1 M 
for a total volume of 50 mL was enough to endow the adequate viscosity.  
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LBG was grinded in a glass mortar for reduction of particle size, followed by the addition of 
HCl and water. The reduction of particle size increased the contact between the polymer chain 
and the acid molecules. LBG is partially soluble in cold water and needs to be heated to reach 
maximum solubility. This is why the protocol of its solubilisation included the use of 
temperatures up to 85 ºC. This is in line with reports on the literature saying that 
galactomannans having high molecular weight and low galactose content are only soluble at 
high temperatures.85  
Considering both the pH obtained after dissolving the produced LBG MPs in water (pH about 
4.3), which was considered low regarding an in vivo application, and also the results obtained 
in cytotoxicity assays, an attempt was made to reduce the final concentration of HCl in 
microparticles. HCl at concentrations of 0.01 and 0.001 M was thus tested. Unfortunately, 
none of the concentrations was successful in providing the adequate viscosity for spray-drying 
and the initial conditions (0.1 M HCl) were decided to be used. Another attempt was made 
associating the addition of 0.01 M HCl (10 mL in a final volume of 50 mL) with the heating of 
LBG dispersion in water-bath at 55 ºC during the spray-drying process. Although a certain 
reduction of viscosity was appreciated, this was not enough to obtain an acceptable yield of 
spray-drying. The more significant reduction of viscosity in presence of HCl 0.1 M is attributed 
to high concentrations of H+ in solution, which cause a weak deprotonation of hydroxyl groups 
of water and galactomannan molecules, resulting in the reduction of the number of hydrogen 
bonding. With a lower number of hydrogen bonds being established between water and LBG, 
and between the proper LBG molecules, there is less expansion of the LBG chain and, 
therefore, fewer interactions of galactomannans occur, causing viscosity reduction.85   
The addition of salts, such as NaCl, KCl and CaCl2 at concentrations between 5 and 50 mM is 
also reported as strategy to reduce the viscosity of LBG dispersions, and could be used in 
future approaches.  
 
4.2. Characterisation of microparticles 
LBG microparticles were successfully obtained in a one-step spray-drying process and several 
formulations were produced. In general, and as observed in Figure 4.1, MPs presented 
irregular shapes and a convoluted/wrinkled surface. 
For the formulations LBG.RFB and LBG.INH.RFB the shown microphotographs are 
representative of each group, as of these being composed of various formulations containing 
different amounts of RFB.  
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Figure 4.1: Microphotographs of LBG-based microparticles viewed by scanning electron 
microscopy. A) Unloaded LBG Microparticles; B) LBG.INH = 10:1 (w/w); C) LBG.RFB = 10:0.5 (w/w); 
D) LBG.INH.RFB = 10:1:0.5 (w/w). 
 
These morphologies are similar to  those reported for other polysaccharide microparticles 
produced by spray drying.86–88 The affinity between a determined polymer and the solvent 
used in spray-drying are factors conditioning the morphological aspect of MPs. In fact, when 
the droplets of polymer dispersion start drying, a film of polymer is first formed on the surface 
that might interfere with diffusion of water from the inside out. This leads to an increase of the 
internal pressure that might reach a critical point where the particle deforms or even 
disintegrates.87 The irregular morphologies could improve dispersibility and flow properties of 
dry powders, because surface irregularities reduce the contact between MPs and the 
possibility of establishing van der Waals forces that lead to agglomeration.47,87  
The aim of this work, as previously established, was to develop microparticles of LBG with 
adequate aerodynamic properties for pulmonary administration with the particular requirement 
of reaching the alveolar zone. This is where alveolar macrophages, host of mycobacteria, 
reside. From a macroscopic observation, RFB-loaded microparticles had very acceptable flow 
properties, which were better than those observed for microparticles devoid of RFB. This 
suggests a favorable effect of RFB on microparticle flowing properties. However, more 
rigorous characterization of aerodynamic properties is required, relying on properties such as 
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Feret’s diameter, density and aerodynamic diameter. Tables 4.1 and 4.2 present the results of 
this characterization.  
 
Table 4.1: Spray-drying production yields and microparticle Feret’s and aerodynamic diameters 
(mean ± SD, n = 3)   
Drug:Polymer Ratio 
Production Yield 
(%) 
Diameter (µm) 
Feret’s Aerodynamic,  = 1.2 
Unloaded LBG  70.1 ± 4.1 1.35 ± 0.73 1.45 ± 0.05 
LBG.INH 10:1 66.0 ± 5.8 1.50 ± 0.80 1.67 ± 0.20 
LBG.RFB 
10:0.2 61.5 ± 0.7 1.26 ± 0.63 1.40 ± 0.20 
10:0.5 67.0 ± 2.8 1.10 ± 0.56 1.15 ± 0.01 
10:1 70.1 ± 4.8 1.50 ± 0.86 1.62 ± 0.04 
LBG.RFB.INH 
10:1:0.5 58.7 ± 5.9 1.11 ± 0.58 1.24 ± 0.01 
10:1:1 71.7 ± 3.2 1.60 ± 0.17 1.77 ± 0.15 
INH: Isoniazid; LBG: Locust Bean Gum; RFB: Rifabutin 
 
Table 4.2: Microparticle real, bulk and tap densities and Carr’s index (mean ± SD, n = 3)   
Drug:Polymer ratio 
Density (g/cm3) Carr’s 
Index (%) Real Bulk Tap 
Unloaded LBG 1.39 ± 0.01 0.24 ± 0.06 0.37 ± 0.08 34.32 ± 0.93 
LBG.INH 10:1 1.41 ±0.02 0.24 ± 0.01 0.36 ± 0.00 34.52 ± 2.06 
LBG.RFB 
10:0.2 1.41 ± 0.03 0.20 ± 0.01 0.32 ± 0.05 36.80 ± 2.74 
10:0.5 1.33 ± 0.03 0.15 ± 0.04 0.25 ± 0.07 40.10 ± 0.65 
10:1 1.39 ± 0.02 0.14 ± 0.02 0.25 ± 0.02 42.89 ± 4.11 
LBG.RFB.INH 
10:1:0.5 1.43 ± 0.01 0.11 ± 0.00 0.19 ± 0.01 43.72 ± 1.50 
10:1:1 1.45 ± 0.01 0.13 ± 0.03 0.24 ± 0.05 45.35 ± 1.44 
INH: Isoniazid; LBG: Locust Bean Gum; RFB: Rifabutin 
 
Spray-drying yields varied between 59% and 72%, which are considered satisfactory and are 
similar to others found in literature for spray-dried polysaccharides.86,87  
The particle size of a powder formulation proposed for inhalation is, together with the particle 
density, a prominent factor in the success of formulation, because it strongly influences the 
sedimentation and dispersion proprieties of the powder.89 As mentioned before, the 
aerodynamic diameter of particles aimed at reaching the alveolar zone after inhalation should 
be of approximately 0.5 – 2 µm,27 while a size of 1 - 2 µm is known to favour the phagocytosis 
by alveolar macrophages.63 Among the various MP formulations that were developed, no 
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relevant differences were found on the Feret’s diameter, which varied from 1.10 µm to 1.60 
µm. Real, bulk and tap densities are also very similar amongst the seven formulations, with 
real density registering values of 1.3 or 1.4 g/cm3, very common values for spray-dried 
samples.87,90,91 Bulk densities varied between 0.1 and 0.25 g/cm3 and tap densities registered 
a slight increase in comparison with the former, which is expected because of the method 
used for the determinations. These results are identic to obtained for the microparticles 
obtained though SPD.92–94 The real density values, along with Feret’s diameters, resulted in 
aerodynamic diameters between 1.27 – 1.90 µm. The morphology of these MPs is similar to 
that of the pollen-shaped particles described by Hassan et al.30 Those were referred to closely 
resemble a spherical shape, but the irregular surface would cause a slightly higher shape 
factor as compared with spherical particles. This has a consequence in the calculation of Daer, 
which considered the dynamic shape factor of 1.2, the same reported for the referred pollen-
shaped particles.30 The determined aerodynamic diameters are theoretically suitable for deep 
lung deposition upon inhalation,27 although experimental determination of Daer would be 
important to support this claim.75  
The Carr’s index is one of the parameters used to infer on the flowabiliy of a powder and it is 
considered that values below 25% are indicative of good flowing properties.30 In this work, the 
calculated values varied within 34% and 45%, and microparticles associating both drugs were 
those showing the worst values, in spite of the good flowing properties estimated 
macroscopically.  In a further development of the work, the aerosolisations properties of the 
formulations from a dry powder inhaler will be tested and if a eficient aerodynamic behaviour is 
verified, a solution might comprise the incorporation of adjuvant excipients such as leucine, an 
amino acid with demonstrated ability to improve aerosolization properties.94   
 
4.3.  Association efficiency 
In developing an effective drug formulation, it is important to succeed on drug association. 
However, the process of association is affected by process variables, as the drug-polymer 
ratio, solvent, use of crosslinking agents, etc. Spray-drying is a technique usually providing 
high association efficiencies.49,87 In the microparticles produced in this thesis, the percentage 
of drug associated is higher than 80%, as indicated in table 4.3.  
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Table 4.3: Drug association efficiency and loading capacity (mean ± SD, n = 3) 
Drug:Polymer Ratio Association Efficiency (%) Loading Capacity (%) 
LBG.INH 10:1 88.8 ± 1.5 8.8 ± 0.1 
LBG.RFB 
10:0.2 92.4 ± 6.0 1.8 ± 0.1 
10:0.5 86.3 ± 3.0 4.1 ± 0.1 
10:1 102.81 ± 3.8 10.2 ± 0.4 
LBG.RFB.INH 
 INH RFB INH RFB 
10:1:0.5 82.8 ± 4.7 91.5 ± 4.1   7.3 ± 0.4 4.0 ± 0.2 
10:1:1 87.9 ± 8.0  92.70 ± 7.7 7.9 ± 0.7 8.4 ±  0.4 
INH: Isoniazid; LBG: Locust Bean Gum; RFB: Rifabutin 
 
The association efficiency is a ratio between the real quantities of drug and the theoretical 
quantity of drug what was encapsulated. In turn, loading capacity concerns the real quantity of 
drug in a mass of microparticles. Despite the differences in the solubilities of isoniazid and 
rifabutin (125 mg/mL versus 0.19 mg/mL),23,24 the two drugs could be incorporated within the 
LBG matrix with approximately equal efficiency. Isoniazid, owing to its hydrophilic nature, is 
easily incorporated in aqueous solutions, allowing obtaining high association (80 – 90%). 
These results are similar to those reported for other spray-dried formulations containing this 
drug.95–97  
RFB is a lipophilic drug and its association required some optimizations. An adjuvant effect 
was tested using Tween 80® and HCl at different concentrations (0.001, 0.01 and 0.1 M). At 
the end, HCl 0.01 and 0.1 M were those yielding better association. In acid medium the 
hydrophobic molecule (Figure 1.5 B) is deprotonated, allowing an increase of its solubility in 
water and adequate incorporation in LBG dispersion. The concomitant trituration of LBG and 
RFB powders, further allowed increasing the loading of RFB. The incorporation of RFB in 
microparticles was tested at different ratios. The association efficiencies varied within 85-100% 
which is considered a good result. In formulations containing RFB only, it was when RFB was 
present at the ratio of 10:1 that the higher value of association was registered (around 100%, p 
< 0.05). When both drugs were incorporated, the association of RFB was still high, but 
decreased to approximately 90%. The results are similar to those obtained by Muttil et al., who 
developed INH- and RFB-loaded poly(lactic acid) microparticles obtained by spray drying.98 
Regarding the loading capacity, it varied between 2 and 10%, approximately respecting the 
theoretical loadings in most cases owing to the high association efficiencies. 
In this thesis, the co-encapsulation of INH and RFB in inhalable LBG MPs was envisaged, 
complying with the requirements of WHO for a tuberculosis therapy comprising an association 
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of drugs. MPs formulations containing each of the drugs individually were also produced to 
enrich the state of the art, as LBG MPs were never reported before. 10,38,99,100 However, the 
target formulation is considered that combining both drugs. The choice of RFB instead of RIF, 
the latter being the most used drug in tuberculosis therapy along with INH, was due to the fact 
that RIF and INH form adducts when together in solution, which would be a limitation in 
microparticle formation.100     
 
4.4.  In vitro drug release  
In vitro drug release studies were performed at 37 ºC, to mimic physiological temperature, in 
two media. The alveolar lung lining fluid has a pH of approximately 7,101 and its composition 
consists of an aqueous solution102 having a considerable content of surfactant proteins and 
phospholipids.103 The dissolution media selected for evaluation of isoniazid release was PBS 
pH 7.4, that has been described as suitable for this application, resembling the local pH.73,104 
However, rifabutin is a hydrophobic molecule and, therefore, it was necessary to include a 
surfactant into the dissolution media (Tween 80) to enable drug dissolution and 
quantification.104 Thus, the used medium every time RFB was present in the evaluated 
formulation, was PBS pH 7.4 added of 1% (v/v) Tween 80. As Tween is a tensioactive, this 
medium further resembles the lung lining fluid in a proper way, as this is composed as 
phospholipids, as mentioned above.  
After phagocytosis, the microparticles are expected to be included in a phagosome that will 
then fuse with lysosome, forming the phagolysosome.98 Inside this structure, microparticles will 
be digested and release the drug. The phagolysosome contains proteolytic enzymes, oxygen 
radicals, chelator precipitators and has a pH varying between 4.5 and 5.5.105  In order to 
resemble this medium, a release medium of pH 5 (citric acid/sodium hydroxide solution) was 
also selected to perform release studies, as reported in other works.98 It is important to 
highlight that, if microparticles are co-localized with bacteria in maturation-arrested 
phagosomes, the pH of these structures is 7.498 and, therefore, the other medium might 
resemble this condition regarding the pH. 
It is also relevant to refer that the volume of alveolar lung lining fluid or phagolysosome 
represents only a residual amount of liquid. Taking this into account, the method used in this 
thesis to perform the determination of release profile, which is the generally reported and 
which follows the European Pharmacopea methods,73 might not provide results resembling 
exactly what occurs in vivo. Although conscious of these issues, a volume of dissolution media 
had to be selected so that the drug dissolution conditions and quantification procedures were 
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not compromised.73 Even if not absolute accurate, it is believed that the obtained results give 
an indication on the expected behaviours.  
The in vitro release profiles of INH from LBG.INH MPs in two media described above are 
plotted in figure 4.2. A rapid release was observed in both media, with 70% - 80% of the drug 
being released approximately at 20 minutes. The release is apparently a little slower in pH 5, 
at least for the initial times. In this regard, 31% INH was detected at 10 minutes when the 
assay occurred in pH 5, while 61% were quantified at pH 7.4 for the same period, and 
statistically significant differences were found between two media (p < 0.05). For this 
formulation, the maximum release was registered at about 240 minutes. In general, this profile 
of INH release is identical to that obtained by Zhou et al. when testing PLA microparticles in 
PBS pH 7.4 and pH 5.97  
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Figure 4.2: In vitro release of isoniazid (INH) from LBG.INH (10:1, w/w) microparticles, in pH 5 
(blue line) and pH 7.4 (purple line) during 1440 minutes (24 hours). (Mean ± SD, n = 3).  
 
The rapid release that is observed is possibly due to three factors. First, the high specific 
surface area of these wrinkled MPs, which provides great contact with the release media. 
Second, the low particle density suggests that the internal structure might not be compact, 
which may facilitate the diffusion of INH through the LBG matrix.87 A third reason might rely on 
the apparent absence or very low crystallinity pattern of INH, thus potentiating a rapid 
dissolution in release media.98 
The in vitro release profiles of INH and RFB from LBG.INH.RFB 10:1:0.5 MPs in PBS.Tween 
80® are depicted in figure 4.3. Curiously, it was observed that the profile was slower for both 
the drugs. RFB reaches 100% of release after 180 minutes and INH at 120 minutes. This 
shorter time taken by INH to completely release, as compared with RFB, might be justified by 
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its strong hydrophilic character. No statistically significant differences were found between the 
release profiles of both drugs, except at time point of 120 minutes. The sustained release that 
is observed has certainly a contribution from the gelling ability of LBG. When the assay starts 
and microparticles initiate the contact with the aqueous medium, the polymer matrix gradually 
begins to hydrate from periphery to center, forming a gelatinous swollen mass, which 
progressively allowed the release of drugs into the medium.106  
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Figure 4.3: In vitro isoniazid (blue) and rifabutin (red) release from LBG.INH.RFB (10:1:0.5) 
microparticles in pH 7.4. (Mean ± SD, n = 3).  
 
When comparing figures 4.4 and 4.5, it is seen that the release profile of INH in pH 7.4 differs 
between the formulations LBG.INH (10:1) and LBG.INH.RFB (10:1:0.5). In this regard, the co-
encapsulation with RFB yielded a much slower release, as already said, with only 53% being 
released at 30 minutes, while in the formulation as single drug the same period registered a 
release of 86% (p < 0.05). One possible explanation for this effect is that RFB, when present 
in the microparticles, acts as surfactant98 and somehow retains INH within the matrix for a 
longer time. Nishino et al. have verified that surfactant incorporation into polylactide matrix 
results in reduction of initial burst release of the encapsulated drug (irinotecan).107  
 
4.5. Crystallinity pattern of MP 
X-ray diffractograms of the drugs before and after spray drying are presented in figure 4.4 for 
INH and figure 4.5 for RFB. INH was prepared as aqueous solution and RFB as acid solution.  
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Figure 4.4: XRD spectra of Isoniazid before (BSD) and after spray drying (ASD).  
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Figure 4.5: XRD spectra of Rifabutin before (BSD) and after spray drying (ASD).  
 
INH displayed a profile corresponding to a crystalline drug and the obtained diffraction pattern 
is similar to that described in the literature. INH has sharp and intense peaks at 2 of 14º, 16º 
and 20º (among others), which are characteristic of its crystalline nature.108 After the process 
of spray drying, a decrease in the intensity of some of the peaks was observed. This indicates 
that spray-drying itself changes the crystallinity of INH, probably as a consequence of drug 
recrystallization.109,110  
Concerning RFB, it presented a XRD pattern corresponding to a crystalline drug, identic to the 
obtained in other analysis.111  This profile presents characteristic peaks appeared in  the XRD 
pattern of pure RFB at a diffraction 2 angle of 10.75, 12.63, 15.50, 17.9, 18.9 and 22.8 
(among others).111 After spray-drying, no diffraction peaks were observed suggesting an 
amorphous state or the presence of very small crystals not identified by XRD.  
X-ray diffractograms of LBG polymer, unloaded LBG MPs and drug-loaded LBG MPs are 
presented in figure 4.6. For the formulations containing RFB, the diffractograms of LBG.RFB 
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10:1 and LBG.INH.RFB 10:1.1 are presented, which are considered representative of the 
other ratios. 
5 10 15 20 25 30 35 40 45 50 55 60
2Theta (degrees)
LBG polymer Unloaded LBG MP LBG.INH LBG.RFB LBG.INH.RFB
 
Figure 4.6: XRD spectra of locust bean gum (LBG) raw material and spray dried formulations: 
LBG raw material (brown line), unloaded LBG MPs (green line), LBG.INH 10:1 MPs (blue line), 
LBG.RFB 10:1 MPs (red line), LBG. INH.RFB 10:1:1 MPs (orange line). INH: Isoniazid; LBG: Locust 
bean gum; RFB: Rifabutin.   
 
Locust bean gum does not show diffraction peaks, in agreement with its non-crystalline nature. 
Diffractograms obtained after and before spray drying are similar comparing to each other, and 
are also similar to those described in literature.112 RFB shows peaks with lower intensity than 
INH, as shown in figures 4.4 and 4.5. Therefore, some diffraction peaks at least from INH were 
expected to be observed in microparticle formulations. In those containing INH (LBG.INH and 
LBG.INH.RFB), no diffraction peaks were identified. The diffractograms are identic among 
themselves and also similar to that of the polymer. This observation is common to other spray-
dried microparticles,42,95,109,113 where INH peaks disappeared in INH-loaded microspheres, only 
peaks from the matrix material being observed. This absence of INH peaks might be due to 
the fact that very small crystals appeared after INH recrystallization, which are under the 
detection limit of the equipment.108 It can also be justified by the rapid process of drying 
occurring in spray-drying, which affects crystal rearrangement, leading to the formation of an 
amorphous structure.49 High inlet temperatures used in the process have also been referred in 
the literature to possibly affect the final structure.114 In this regard, the production of INH-
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loaded microparticles was performed at 120 ºC, but no differences on crystallinity were found 
(data not shown), indicating an absence of effect of inlet temperature in this case. 
Interestingly, the physical mixture of LBG and INH in the same polymer/drug ratio present in 
the formulation, has shown the INH peaks in the diffractogram (data not show), which 
reinforces that the proper spray-drying process is leading to a loss of crystallinity.  
 
4.6. Cell characterisation 
The drug delivery approach proposed in this thesis was designed for inhaled TB therapy. As 
described, the microparticles present, at least from a theoretical point of view, an adequate 
Daer to reach the alveolar zone, where they are expected to undergo phagocytosis by alveolar 
macrophages. For this reason, it was necessary and fundamental to perform analysis on the 
interaction of particles with the cells present in the alveolar zone. This zone is composed by 
alveolar epithelium cells, surfactant and alveolar macrophages, as described in figure 4.7. 
 
Figure 4.7: Interaction between aerosol particle and alveolar epithelium: When microparticles 
reach the alveolar zone, and deposit over the epithelium, their dissolution and consequent release of 
drug (1) might occur. The drug might penetrate the epithelium and reach the systemic circulation for 
systemic action (2), or act locally (1), or the microparticle can be phagocytosed by macrophages (3). 
Adapted from Carvalho et al.115  
 
Cell culture models have been applied to investigate the interactions occurring between cells 
and drug delivery systems, including the study of processes such as phagocytosis, cell 
signaling pathways and cellular activation, apart from permitting an evaluation of toxicological 
events. Cell culture assays have been indicated in many cases as adequate to replace in vivo 
studies at initial stages of research. Therefore, it is essential that the established in vitro 
setups are accurately defined in order to mimic in vivo conditions the better possible. The cell 
culture studies included in this thesis were performed in three different cell lines, which 
selection is reasoned below.  
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A549 cells are a widely accepted model of the alveolar epithelium and derive from lung 
adenocarcinoma. Morphologically, these cells present several multilamellar cytoplasmic 
inclusion bodies, similar to those found in human lung alveolar type II cells. 
As the drug carriers designed in this thesis are aimed at targeting the alveolar macrophages, it 
was important to also have cell lines representing macrophages. Human alveolar 
macrophages are represented by differentiated THP-1 cells, which are human leukemic 
monocytes. The differentiation performed with PMA, according to a protocol disclosed in the 
methods section, results in differentiated THP-1 cells that are reported to have alveolar 
macrophage characteristics.115,116 A cell line of rat alveolar macrophages, NR8383, was also 
used to enable the establishment of comparisons between human and rat responses.  
As referred above and in methods section, THP-1 cells in the monocyte state can be 
differentiated into a macrophage-like phenotype using either macrophage colony-stimulating 
factor, phorbol-12-myristate-13-acetate, or 1α, 25-dihydroxyvitamin D3.35 In culture, THP-1 
monocytes have a round shape and are in suspension in CCM. When contact with PMA is 
provided, several morphological, physiological and genetic alterations occur that lead to a 
differentiation into macrophage-like cells.80 Figure 4.8 shows the morphologies of THP-1 and 
macrophage-differentiated THP-1 cells, which are representative of what was observed in our 
cell culture and experiments.  
 
Figure 4.8: Macrophage differentiation from THP-1 cells: (A) Round shape THP-1 cells were 
exposed to 100 nM phorbol-12-myristate 13-acetate (PMA), and after 48 hours (B) macrophages were 
obtained, showing flattened and adherent cell morphology. Adapted from Raffetseder et al.117  
 
Firstly, the concentration of PMA and time of exposure were optimized in THP-1 cells cultured 
in 6-well plates at a density of 1.0 x 106 cells per well in 5 mL of RPMI. The conditions tested 
were: 5, 10, 50, 100 and 200 nM PMA four 3 days. In our conditions, it was verified that 50 nM 
with 48 hours of exposition was adequate for differentiation of THP-1 cells into macrophages, 
by observation that the macrophages exhibited an adhering phenotype onto the wells surface, 
as described in figure 4.8, and according to the literature.35,80   
A B 
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Apart from the observation of the adhering phenotype, several other methods have been 
described as more accurate for the characterization of fully differentiation of macrophage-like 
THP-1 cells. These include the expression of differentiation-dependent cell surface markers 
such as CD-14, CD36, TLR-2, and CR3 (CD11b/CD18).80 The analysis of the cells (before and 
after differentiation) by flow cytometry, confirmed that differentiated cells present a distinct size 
(figure 4.9, panels A and B). This observation is concordant with that related by Grabowski.35 
Furthermore, an immunocytochemical characterisation might help on the confirmation of the 
correct phenotype. In this regards, an increase in the expression of CD11b is reported to be 
visible only on macrophage-differentiated THP-1 cells.80 In our work we have confirmed the 
presence of this CD11b antibody in the population of THP-1 differentiated cells, as seen in 
panel C of figure 4.9. The percentage of undifferentiated THP-1 cells evidencing signal of the 
same antibody was considered residual, an effect that has been described by other authors. 35 
 
Figure 4.9: Immunocytochemical characterization of THP-1 cells and macrophage-differentiated 
THP-1 cells. Evaluation and comparison between size (axis FSCH) and structure/complexity (axis 
SSCH) of THP-1 (A) and macrophage-like THP-1 cells (B). One group of THP-1 cells was incubated for 
48 hours with 50 nM of PMA, allowed their differentiation into macrophages-like THP-1. Marker anti-CD 
11b allows distinguishing the population of undifferentiated THP-1 from THP-1 differentiated cells (C). 
This marker labels the CR3 receptor, present only in membrane of THP-1 differentiated cells. Results 
expressed as mean ± SEM. 
 
 
A 
B 
C 
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4.7.  Cytotoxic evaluation 
The evaluation of the biocompatibility profile of formulations designed for drug delivery is an 
up-to-date subject, referred as mandatory for any formulation being proposed.118 This 
evaluation was performed in two cell lines, representing the alveolar epithelium (A549 cell line) 
and alveolar macrophages (THP-1 cells). For the analysis of pharmaceutical formulations, 
different in vitro tests have been employed that allow evaluating the integrity and function of 
different structures of cells after exposure to drug formulations. In this regard, this thesis 
encompassed the evaluation of metabolic activity (MTT assay) and membrane integrity (LDH 
release assay).  
 
4.7.1. Samples presented in solution/suspension 
The cytotoxicity evaluation (MTT) was analysed at two time points (3 and 24 hours) for each 
cell line and for each sample presented in solution/suspension. These assay times correspond 
to short and long term exposure of cells to the formulations,119 and are usually applied in this 
type of analysis of pulmonary drug delivery systems.119,120 For analysis and interpretation of 
results, it was considered that a sample evidences cytotoxic potential when cell viability values 
resulting from exposure to the material decrease to values below 70% (in all figures is 
indicated with dashed line), as indicated by the ISO 10993-5.121    
For each cell line, the MTT assay protocol was adapted as a function of results obtained in 
optimization experiments. For THP-1, for instance, it was necessary to use SDS to dissolve 
formazan crystals, instead of DMSO.122,123  
The cytotoxic evaluation of RFB as free drug required a previous solubilisation in DMSO at 
concentration 20 mg/mL (w/v), due to its hydrophobic character. After this, it was possible to 
perform the dilution of this solution in CCM to obtain the desired concentrations to be tested. 
Given the need to use DMSO, a cytotoxic evaluation of the solvent itself was also performed in 
both cell lines, between concentrations of 0.0313% and 2% (v/v). It was demonstrated an 
absence of cytotoxicity of DMSO at the tested concentrations (data not show). Specifically, for 
DMSO concentration of 0.5% (v/v), used in tested RFB solutions, registered cell viabilities 
corresponded to 100 ± 4% in A549 cells and 94 ± 3% in THP-1 cells.  
In A549 cells, the cytotoxic evaluation of drugs after exposure for 3 and 24 hours is presented 
in figure 4.10. The same evaluation was performed for macrophage-like THP-1 cells, which is 
depicted in figure 4.11. For both cell lines, pure RFB demonstrated to induce a reduction of 
cell viability in higher concentrations after 24 hours of exposure (p < 0.05). A concentration- 
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and time-dependent effect was observed for this drug. On the contrary, INH did not show any 
detrimental effect on cell viability. 
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Figure 4.10: A549 cell viability after 3 and 24 hours of exposure to Drugs. INH: Isoniazid; RFB: 
Rifabutin; Results expressed as mean ± SEM. Dotted line represents 70% cell viability. 
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Figure 4.11: Macrophage-differentiated THP-1 cell viability after 3 and 24 hours of exposure to 
Drugs. INH: Isoniazid; RFB: Rifabutin; LBG: Locust bean gum. Results expressed as mean ± SEM. 
Dotted line represents 70% cell viability. 
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The analysis of effect on cell viability of a solution prepared with the raw material (LBG) after 3 
and 24 hours of exposition is presented in figure 4.12 for both cell lines. A549 cells 
demonstrate a clear reduction of cell viability at both times of exposure. Macrophage-like cells, 
in turn, seem to be more resistant to the effect of LBG, as cell viabilities remained above 80% 
in all tested conditions.  
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Figure 4.12: Cell viability of A549 and differentiated THP-1 cells after 3 and 24 hours of exposure 
to Raw material (LBG). INH: Isoniazid; RFB: Rifabutin; LBG: Locust bean gum. Results expressed as 
mean ± SEM. Dotted line represents 70% cell viability. 
 
The raw materials used in carrier matrix and the carriers should be evaluated separately,118 as 
it is assumed that the carrier structure might affect the final toxicological behaviour.120 It is 
curious to observe that, already at 3 hours, the LBG as polymer has a stronger effect on cell 
viability of A549 cell line comparing with unloaded LBG microparticles (figure 4.13, p < 0.05). 
For LBG polymer, cell viability was below 70% (about 50-60%) for all tested concentrations. 
This effect remained for up to 24 hours, and was inclusively accentuated at this time, the 
polymer eliciting cell viabilities around 40% independently of the concentration. However, it is 
important to highlight that spray-drying the polymer reverted the effect, and unloaded LBG 
microparticles exhibited a very mild effect, with cell viabilities remaining above 75% in all 
cases, even after 24 hours incubation (Figure 4.13 and 4.14). This effect of LBG as raw 
material might be due to the fact that it presents a bulkier structure and higher size, causing a 
major effect of viscosity on liquid contacting with the cells, which can difficult the gaseous 
exchanges between cells, medium and air, leading to cell death. After spray drying, there is a 
reduction of size, and the suspension corresponding to the microparticle sample is 
macroscopically more fluid than that of LBG polymer. The literature already describes that 
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macrophage-like THP-1 cells are more sensitive to an insult than A549 cells.119 As happened 
for LBG polymer, macrophage-differentiated THP-1 cells did not demonstrate any reduction of 
cell viability upon exposure to unloaded LBG microparticles.   
The cytotoxic evaluation of drug-loaded formulations prepared with LBG is presented in the 
following figures. In general, the obtained results revealed that macrophages respond to these 
microparticles in a similar manner of A549 cells. Figures 4.13 and 4.14 show the results 
obtained upon exposure of A549 cells to unloaded and drug-loaded microparticles for 3 and 24 
hours, respectively. 
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Figure 4.13: A549 cell viability after 3 hours of exposure to formulations. INH: Isoniazid; LBG: 
Locust bean gum. RFB: Rifabutin; Results expressed as mean ± SEM. Dotted line represents 70% cell 
viability. 
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Figure 4.14: A549 cell viability after 24 hours of exposure to Formulations. Formulations with 
different ratio polymer: drug. INH: Isoniazid; LBG: Locust bean gum. RFB: Rifabutin; Results expressed 
as mean ± SEM. Dotted line represents 70% cell viability. 
  
For INH drug, its incorporation in microparticles did not result in a significant decrease of cell 
viability comparing with unloaded LBG MPs, all values being above 75% at 3 hours. The 
prolongation of the exposure to 24 hours revealed only a very slight decrease on cell viability 
to approximately 65% in this case (Figure 4.14). Therefore, no overt cytotoxic effect was 
considered to occur for INH-loaded microparticles. On the contrary, even after a short time of 
exposure (3 hours), RFB-loaded formulations generally evidenced a slight reduction of A549 
cell viability to values below 70%, particularly for concentrations of 0.5 and 1.0 mg/mL (Figure 
4.13). The effect was accentuated after 24 hours exposure, as seen in figure 4.14. RFB-
loaded formulations demonstrated a concentration- and time-dependent effect and, actually, 
for the higher concentration and the longer exposure time, viabilities lower than 20% were 
obtained. Microparticles associating both drugs had a milder effect than those containing RFB 
only, but still a significant cytotoxic behavior was detected. Additionally, formulations having 
different amounts of RFB, demonstrated clear concentration-dependent effect. In these 
microparticles, not so low cell viabilities were found, but the formulation LBG.INH.RFB = 
10:1:0.5 (w/w) still registered around 40% cell viability for the concentration of 1 mg/mL and 
less than 60% at 0.5 mg/mL. 
The cytotoxic evaluation was also performed in macrophage-differentiated cells, results being 
presented in figures 4.15 (3 hours) and 4.16 (24 hours). Again, INH-loaded microparticles 
evidenced no toxic effect, as only after 24 hours exposure a very slight decrease on cell 
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viability was detected, which is devoid of significance as the values remained close to 80%–
90% in all cases. Some authors have reported that INH drug presents an IC50 of 1000 mg/mL 
in alveolar macrophages (isolated from albino rats).124 That study was performed in primary 
cells, thus different from those used in this study, but they mimic in vivo conditions in a closer 
way and in fact indicate that a high amount of INH is necessary to induce cytotoxicity.115 RFB-
containing microparticles elicited a reduction of cell viability, which was also stronger for 
microparticles associating RFB only (cell viabilities as low as 10% after 24 hours), as observed 
previously in A549 cells. The effect was again concentration- and time-dependent.  
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Figure 4.15: Macrophage-like THP-1 cell viability after 3 hours of exposure to Formulations. 
Formulations with different ratio polymer: drug. INH: Isoniazid; LBG: Locust bean gum. RFB: Rifabutin; 
Results expressed as mean ± SEM. Dotted line represents 70% cell viability. 
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Figure 4.16: Macrophage-like THP-1 cell viability after 24 hours of exposure to Formulations. 
Formulations with different ratio polymer: drug. INH: Isoniazid; LBG: Locust bean gum. RFB: Rifabutin; 
Results expressed as mean ± SEM. Dotted line represents 70% cell viability. 
 
The general observation thus corresponds to an increased toxic effect, which reflects in lower 
viabilities, when RFB is included in the microparticles. The literature does not report studies on 
RFB impact in cell viability with the cell lines used in this study, but the high toxicity in vivo is 
well reported.125 The cytotoxic behavior might be due in part to the lipophilic character of RFB. 
It presents a high membrane lipid tropism, resulting in high penetration into infected cells, 
which can impose increased toxicity.126  
Focusing only the results from unloaded LBG MPs and LBG.RFB formulations (10:0.2, 10:0.5 
and 10:1) at 24 hours, there is a statistically significant difference (p < 0.05) for both cells lines. 
It was observed that, while the ratio 10:1 had a strong negative effect on cell viability, a ratio of 
10:0.5 had a milder impact on cell viability. No significant difference was observed between 
formulations 10:0.5 and 10:0.2. As a whole, it is suggested that, apart from an RFB-related 
effect, there is possibly a contribution of the HCl content, which needs to be included in the 
formulation for solubilisation. LBG is believed to not contribute to the toxicological effect, given 
the absence of toxicity of LBG MPs, used as control. Microparticles with association of drugs 
display lower toxicity levels, generating higher values of cell viability, although still below 70% 
in most cases. 
For interpretation of these results, a determination of the effect of RFB dissolved in either HCl 
or DMSO on cell viability was performed in both cell lines. It was determined that 1 mg 
microparticles have 0.0183 mg HCl and the amounts corresponding to MPs concentration of 
0.1 and 0.5 mg/mL were also calculated. RFB was dissolved at 20 mg/mL in HCl 0.1M or 
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DMSO and subsequently diluted with CCM to obtain solutions of RFB at 0.01, 0.05 and 0.1 
mg/mL and with, respectively, HCl concentrations of 0.0018, 0.0091 and 0.0183 mg/mL. The 
obtained cell viability of A549 cells for RFB at 0.1 mg/mL (the higher concentration tested) was 
43.9 ± 2.1% when drug was dissolved in DMSO and 54.7 ± 3.1 when solvent was HCl. The 
latter thus induced higher viabilities, comparatively, although cell viability is considered low. 
However, in macrophage-differentiated cells there was an increase of toxicity of RFB dissolved 
in HCl, cell viability in DMSO being 60.4 ± 2.3% and in HCl being 38.8 ± 3.7%. For both cells 
lines was found a statistically significant differences (p<0.05) between RFB dissolved in DMSO 
and HCl.  The literature does not describe the behaviour of RFB-loaded microparticles in vitro. 
However, RFB-loaded lipid nanoparticles were also demonstrated to reduce significantly A549 
cell viability (50%) for concentrations of nanoparticles containing RFB (1 and 10 mg/mL) 
similar to those observed in these results.31 
In similar project in our laboratory, it was possible to use HCl 0.01M for the solubilisation of 
RFB, in a glucomannan:RFB ratio of 10:0.5 and glucomannanr:INH:RFB ratio of 10:1:0.5, and 
no reduction on cell viability beyond 70% was observed for A549 cells (data not show).  
Although the mechanism might not be well established, the toxic effect is undoubtedly related 
with RFB. In this context, some authors have referred that at acidic pH values, RFB 
establishes more electrostatic interactions with lipid membranes, possibly leading to 
membrane disruption.127   
Notwithstanding the determinations that were made, there is the expectation that the toxicity 
does not translate to in vivo, because the tested doses are supposedly much higher than real 
amounts expected to be in contact with cells after administration. The highest dose of MPs 
tested was 303.03 µg/cm2. The area of epithelial surface of alveolar zone is about 5000 cm2,128 
and if considered that distribution of MPs is uniform, for example a nominal proportion (e.g. a 
third) of an inhaled dose (consider 10 mg) deposits in a defined region (alveolar),90 the dose 
estimated across this area is 0.66 µg/cm2. This dose is about 460 x lower than the 303.03 
µg/cm2 used in our study. Taking this into account, the effects would be much closer to those 
of the lower dose of 0.1 mg/mL to those of the higher dose. Considering the higher number of 
human alveolar macrophages (23 billion) distributed on surface area of human alveoli 
compared to that of the cell culture,129,130 the hypothesized MPs dosage could be argued as 
potentially non-cytotoxic.130 Unfortunately, we could not meet the conditions permitting 
weighing such a lower amount of dry powder that could resemble in a better way the in vivo 
conditions. 
Another reason suggesting that the administration of these microparticles in vivo will not 
induce high cytotoxicity, is the capacity of microparticles to form complexes with polar heads of 
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groups of the phospholipids present in pulmonary surfactant lipids, allowing reaching high 
concentrations without causing damage on alveolar epithelium.127 The higher partition of the 
drug at the studied pH 5.0 comparatively with neutral pH values is in agreement with the 
higher affinity of the drug to the infected cells, allowing to present a higher selectivity and  
higher  concentrations  on  the  pharmacological  target.73,75  
 
4.7.2. Samples presented in aerosol  
It is usual that cytotoxic studies of inhalable formulations perform an evaluation under liquid 
conditions, that is, as a suspension. However, these conditions not really resemble in vivo 
conditions. One of the most relevant aspects is that, after inhalation and, particularly if the 
alveolar region is reached, microparticles will not be submerged in liquid, simply because there 
is no such an amount of liquid permitting so. The lung lining fluid depth (alveolar surfactant) is 
an order of magnitude smaller (0.01 – 0.2 µm) than the diameter of respirable microparticles (1 
– 3 µm).102,103 For this reason, a preliminary assay was setup to perform the cytotoxic analysis 
with microparticles under the form of an aerosol. The literature describes some studies of 
deposition of inhalable particles that use various impactors coupled with tissue culture 
methods in an attempt to mimic in vivo drug deposition. These studies have proven useful in 
complementing in vivo data.103 However, most of the assays designed in such a way are 
applied in transport and uptake studies and no report has been found addressing cytotoxicity.  
For the development of this assay, different aspects were taken into account. First, the method 
for aerolisation of microparticles over cell monolayers was optimised to use the Penn Century 
Dry Powder Insufflator. An optimization of the device operating was performed with three 
formulations, mannitol MPs, unloaded LBG MPs and LBG.INH.RFB 10:1:10 (Figure 4.17).  
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Figure 4.17: Powder delivered from the dry powder insufflator. Mass released after each 
insufflation with of 3 mL of air. Results are expressed as media percentage of initial mass of powder 
loaded in sample chamber and error bars correspond to standard deviation.  
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Dry powder insufflator is described in the literature to be used for dry powder 
characterization,132 uptake,133 and mucoahdesion87 studies. For this study, an optimization was 
performed that included replicating the delivery of each formulation and calculating the mass 
of dry powder to weight before each assay.  
In order to simulate the alveolar environment, and thus obtain results that predict in vivo 
responses, the assay testing samples as aerosols was performed using the cells in absence of 
CCM for a certain period, to simulate the real environment of the alveolar epithelium. The 
assay thus included an initial period of 2 hours where cells were in contact with the samples, 
which were aerosolised over the cell layers devoid of CCM. When CCM was aspirated, a very 
thin layer of liquid remained to maintain the hydration of cells. After that period, a determined 
amount of medium was added for the rest of the assay to not compromise the cell viability due 
to dryness. Some preliminary assays were performed that demonstrated no significant effect 
of the absence of CCM on cell viability for the period of 2 hours. Ideally, the cells should be 
exposed to an amount of volume that resembled the alveolar surfactant, but this volume was 
not possible to reproduce in in vitro conditions, as it is too short an amount. Alveolar surfactant 
content can be estimated as approximately 36 mL,102 covering the alveolar zone that has an 
area of 5000 cm2.102,134 In this manner, the volume of alveolar surfactant can be estimated is 
7.2 µL/cm2. In 12-well plates, or 6-well plates, the volume to add would be respectively, 27.72 
µL and 69.12 µL. These volumes are measurable, but not enough to cover the entire area of 
the cell layer.102 Instead, volumes of 250, 500 and 750 µL were tested and it was found that 
500 µL was the volume not compromising   cell viability.  
Cytotoxicity assays performed upon sample aerosolisation tested two different doses, 303 and 
50 µg/cm2. The formulations selected to be tested were unloaded LBG MPs and the 
formulation with both drugs, LBG.INH.RFB 10:1:0.5. Figure 4.18 depicts the macrophage 
viability after 24 hours exposure of two different doses tested of unloaded LBG MPs and 
LBG.INH.RFB 10:1:0.5. 
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Figure 4.18: Macrophage-like THP-1 cell viability after 24 hours of exposure to unloaded LBG 
MPs and LBG.INH.RFB 10:1:0.5 formulations at two doses. Results expressed as mean ± SEM.  
 
The highest dose induces a greater reduction in cell viability for both formulations (p < 0.05). 
When the dose was reduced to 50 µg/cm2, higher cell viabilities were observed. In this case, 
drug-loaded microparticles were observed to induce a much lower viability (around 35%, p < 
0.05) than unloaded microparticles (50%). Unloaded LBG MP, when exposed as aerosol, elicit 
a higher reduction of cell viability comparatively with the exposure as suspension, when the 
same dose is administered (303 µg/cm2). As also referred before, it can be argued that the 
swelling capacity of LBG induces the formation of a viscous polymeric mass that difficult 
gaseous exchanges between air/CCM/cells. The same might happen in LBG.INH.RFB 
10:1:0.5 microparticles, aggravated by the dissolution of RFB in CCM and its direct exposure 
to the cells. 
It is possible that the lower tested dose is still various orders of magnitude above the real 
contact dose in vivo, as exposed in a previous section. Therefore, future design of these 
studies should reduce the dose in order to better mimic the in vivo conditions. As reducing the 
amount of weighed dry powder is not possible, the best solution would be using a larger 
surface for cell deposition. This is quite a new strategy to evaluate the cytotoxicity of inhalable 
dry powders and is recognised to require further optimisation.  
 
4.7.3. Determination of rifabutin IC50 
It was verified that major toxic effect is observed for microparticles containing RFB. In section 
4.7.1 is discussed the RFB toxicity and therefore it was decided to calculate an IC50. The IC50 
value is defined as the concentration of drug required to induce 50% of cell death. IC50 was 
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determined for both cell lines. In A549 cells it was determined to be 100.70 µg/mL (R2 is 
0.999), while for macrophage-like THP-1 cells it was 87.08 µg/mL (R2 is 0.996), indicating the 
higher sensitivity of THP-1 cells, as already suggested in the MTT assays. In formulations 
LBG.RFB whit ratio 10:0.2 and 10:0.5, the maximum drug concentration tested is respectively 
20 and 50 µg/mL. Better results could thus have been expected taking into account the IC50, 
but as referred, the presence of HCl in microparticles is probably leading to a synergic effect 
that resulted in a further reduction of cell viability.  
 
4.7.4. LDH Release 
The release of LDH indicates the disruption of cell membrane, thus permitting the leaking of 
this cytoplasmic enzyme. The loss of intracellular LDH and its release to the culture medium 
is, therefore, an indicator of irreversible cell death due to cell membrane damage.135 The assay 
thus evaluates cell membrane integrity and complements the results obtained by the MTT 
assay. 
For both cell lines, the results obtained with the analysis of LDH release are concordant and 
complement the MTT results above described, reinforcing the observations regarding the 
cytotoxicity of RFB. Comparatively with the LDH released by untreated cells in both cell lines, 
INH does not increase significantly the value of LDH, while for RFB is verified an increase to 
150 - 170%, which is particularly noticeable at the concentration of 0.1 mg/mL. Contrary to the 
observation from the MTT assay, in the present assay A549 cells (Figure 4.19 A) appeared to 
be more sensitive to the effect of the drug than macrophage-differentiated THP-1 cells (Figure 
4.19 B), which present only a significant change at the higher concentration.  
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Figure 4.19: LDH released from A549 cells (A) and macrophage-like THP-1 cells (B) after 24 
hours exposure to the drugs. Amount of LDH released from cells incubated with cell culture medium 
is assumed as 100% (dotted line).  INH: Isoniazid; LBG: Locust bean gum. RFB: Rifabutin; Results 
expressed as mean ± SEM.  
 
LDH release after exposure of A549 (Figure 4.20) and macrophage-like THP-1 cells (Figure 
4.21) to raw material (LBG) and several formulations is depicted below.  
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Figure 4.20: LDH released from A549 cells after 24 hours exposure to LBG polymer, 
microparticles and lysis buffer. Amount of LDH released from cells incubated with cell culture 
medium is assumed as 100% (dotted line).  INH: Isoniazid; LBG: Locust bean gum. RFB: Rifabutin; 
Results expressed as mean ± SEM.  
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Figure 4.21: LDH released from macrophage-like THP-1 cells after 24 hours exposure to LBG 
polymer, microparticles and lysis buffer. Amount of LDH released from cells incubated with cell 
culture medium is assumed as 100% (dotted line).  INH: Isoniazid; LBG: Locust bean gum. RFB: 
Rifabutin; Results expressed as mean ± SEM. 
 
As observed in the figures above, the exposure of both cell lines to the original LBG polymer, 
unloaded LBG microparticles and INH-loaded microparticles did not induce any physiologically 
relevant alteration in the amount of released LDH. However, RFB-loaded microparticles, either 
when drug was associated alone or in combination with INH, elicited a significant increase in 
LDH release, indicating cytotoxicity. For A549 cells, the formulations LBG.RFB 10:0.5 and 
10:0.2 induced a very slight increase in LDH release at both concentrations (around 110-
120%). However, the formulation LBG.RFB 10:1 elicited a stronger increase in LDH release (p 
< 0.05) which reached almost 400% at the concentration of 1 mg/mL, indicating a clear 
concentration-dependent effect. A similar effect was observed for the microparticles 
associating both drugs and containing the same amount of RFB (LBG.INH.RFB = 10:1:1), 
while that of LBG.INH.RFB = 10:1:0.5 exhibited a much milder effect (LDH release around 
150% at 1 mg/mL, p < 0.05).  
THP-1 cells were not as sensitive to the contact with the microparticles, but cytotoxic effects 
were also observed. As seen in Figure 4.21, the formulations LBG.RFB 10:0.5 (at 
concentration 0.5) and 10:0.2 (at concentration 0.05 and 1.0) make a very slight increase in 
LDH release (around 125 – 150%), while the higher concentrations of LBG.RFB 10:0.5 induce 
a strong release of LDH (around 225%). This result is similar to that caused by the exposition 
to LBG.RFB 10:1 in the two tested concentrations (around 220 – 230%). In formulations 
associating both drugs, the results of LDH release are similar to those obtained for 
formulations containing only RFB when the same RFB amount is associated.  
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Although in both cell lines the values reached by RFB-loaded microparticles were much lower 
than those of the lysis buffer, it is clear that RFB has a cytotoxic effect that is dependent on its 
concentration. This is visible when evaluating the same concentration of microparticles having 
different amounts of RFB and when evaluating the same formulation at different 
concentrations. None of the works reporting the application of LBG microparticles provides 
data on LDH release from cells upon exposure to the carriers. The same occurs for drugs, 
which have no available reports on these cell lines, thus impairing more comprehensive 
comparisons. 
 
4.8.  Evaluation of macrophage ability to uptake LBG microparticles 
The pulmonary delivery of antitubercular drugs, upon loading in a carrier system capable of 
undergoing recognition by alveolar macrophages with consequent phagocytosis,63 is proposed 
in this thesis as an improvement to the current oral therapy. The affinity and selectivity of 
alveolar macrophage surface receptors offers a unique opportunity for selective targeting of 
antitubercular drugs.67 In this perspective, the ability of macrophages to uptake LBG 
microparticles was evaluated in two cell lines representing macrophages (macrophage-
differentiated THP-1 cells and NR8383 cells).   
To perform this assay, fluorescently labelled LBG and PVA microparticles were produced, to 
permit the analysis by flow cytometry. The Feret’s diameters of these microparticles were 
similar to that of unloaded LBG MPs.  
An amount of microparticles corresponding to either 250 or 50 µg/cm2 was tested, in line with 
the amounts tested in cytotoxicity assays when samples were presented as an aerosol. The 
microparticles were exposed to the cells in the form of aerosol and the contact was allowed for 
2 hours. Phagocytosis is a fast process, usually 50–75% of the particles are phagocytosed in 
2–3 hours, 90% or more by 10 hours, and nearly 100% by 24 hours after particle deposition.136 
The time for occurrence of phagocytosis for allowing a differential uptake is 2-3 hours. The 
selected time of 2 hours, which is deemed adequate for the occurrence of phagocytosis, was 
also used by other authors.137 In order to simulate the alveolar environment, the assay was 
performed in the absence of CCM, only a very thin layer of liquid remained to maintain the 
hydration of cells. 
At the higher dose, the percentage of macrophages-differentiated THP-1 cells that 
phagocytosed fluorescently-labelled LBG microparticles was 99.63 ± 0.18%. A very similar 
value (99.50 ± 0.43%) was determined upon reduction of the dose to 50 µg/cm2. This 
evidences an absence of effect of the concentration and suggests a high affinity of 
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macrophages for LBG microparticles. Other microparticles also developed by the research 
team, for instance composed of fucoidan or carrageenan, evidenced a lower ability for 
macrophage targeting (data not shown). Also relevant is the fact that the dose of 50 µg/cm2 
indicated for other polymers a dose-dependent process,63 which did not occur for LBG. Figure 
4.22 depicts the histogram obtained from the cytometry analysis of two populations of 
macrophage-like THP-1 cells, the blue line evidencing the results for cells not exposed to 
fluorescently-labelled LBG MPs, while the orange line corresponds to the results elicited by 
fluorescent microparticles. In the latter, an intense fluorescent signal is observed indicating the 
uptake of microparticles by macrophages. 
 
Figure 4.22: Fluorescent signal of macrophage-differentiated THP-1 cells upon 2 hours exposure 
to 50 µg/cm2 of unlabelled LBG microparticles (blue line) and fluorescently-labelled LBG 
microparticles (orange line). Cells not exposed show auto-fluorescence, while cells exposed to 
fluorescent MPs increase the fluorescence signal, and the population moves to the right, in the axis of 
FL1-H, which reflects the intensity of fluorescence.   
 
Figure 4.23 represents the histogram also obtained by flow cytometry analysis of two 
populations of NR8383 cells. The construction is identic to the one mentioned above and the 
obtained results are also similar to those elicited by differentiated THP-1 cells. Although 
phagocytosis is occurring, a strong increase of intensity as that observed in human 
macrophages was not registered.  
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Figure 4.23: Fluorescent signal of NR8383 cells upon 2 hours exposure to 50 µg/cm2 of 
unlabelled LBG microparticles (blue line) and fluorescently-labelled LBG microparticles (orange 
line). Cells not exposed show auto-fluorescence, while cells exposed to fluorescent MPs increase the 
fluorescence signal, and the population moves to the right, in the axis of FL1-H, which reflects the 
intensity of fluorescence.   
 
Alveolar macrophages are predominant cells in the uptake of inhaled particulates from the 
alveolar region.63 In the two lines representative of macrophages, human and rat derived, it 
was compared the uptake of fluorescently-labelled PVA and LBG microparticles at the dose of 
50 µg/cm2 (figure 4.24).   
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Figure 4.24: Uptake of fluorescently-labelled PVA and LBG MPs by macrophage-differentiated 
THP-1 cells and NR8383 cells upon exposure to 50 µg/cm2 for a period of two hours.  Results 
expressed as mean ± SEM.  
 
It is observed that both cell lines showed high percentage of phagocytosis of LBG 
microparticles. PVA microparticles were also strongly phagocytosed by THP-1 cells, no 
significant statistical difference being observed when comparing with LBG microparticles. In 
turn, a statistical significant difference was obtained for NR8383 cells, almost 94% 
macrophages phagocytosing LBG microparticles while only 53% phagocytosed PVA 
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microparticles (p < 0.05). This observation is indicative of non-preference of NR8383 by this 
polymer.  
LBG has in its chemical structure mannose and galactose, these units being reported to be 
recognised by macrophage receptors, promoting phagocytosis.17 Mannose receptor CD 206, 
can be involved in this specific recognition.66 PVA is an alcohol, composed of repeating units 
of (-[CH2-CH(OH)]-).72 As it does not present specific groups recognized by macrophage 
receptors, it was selected as control in this assay.  
The detection and phagocytosis of inhaled microparticles by alveolar macrophages mainly 
occurs through a series of recognition receptors, called scavenger receptors. This family of 
receptors includes the mannose receptor (CD 206),17 and is responsible for the process of 
recognition of foreign particles and subsequent propagation of phagocytosis.63  The mannose 
receptor, specifically, is reported as capable of recognising mannose, N-acetylglucosamine 
units and sulphated sugars.17 When THP-1 cells were exposed to 50 nM of PMA, a 
differentiation occurred  from which resulted macrophages in the state of activation M0.61,138 In 
this state of activation, it has been reported that macrophages do not express receptors of this 
family,17,139 but only express receptors of the family of Toll-like receptors (TLRs) and  
immunoglobulin superfamily (Fc receptors).129 TLRs present a central role in the innate 
immune response; although not mediating the phagocytosis, these receptors are responsible 
for recognizing foreign particles and intracellular pathogens, leading to the engulfment of these 
by macrophages.140,141 Considering these assumptions, it is possible that when microparticles 
based on PVA or LBG were presented to macrophages, no specific recognition mediated by 
the receptor CD206 occurs, which a possible explanation for the similar results is obtained in 
THP-1 cells. In turn, NR8383 cell line is a mannose receptor positive, which means that the 
cells naturally express a functional mannose receptor in cell culture.142 Therefore, when LBG- 
and PVA-based microparticles were exposed to alveolar rat macrophages, a preferential 
affinity for LBG was verified, thus resulting in higher uptake of these microparticles.  
Nevertheless, in both cases it is likely that TLR receptors just recognised the microparticles as 
foreign particulates, promoting the uptake.129 It is important to highlight that macrophages are 
endowed with a natural ability to uptake particulates63 and, therefore, a certain degree of 
phagocytosis was expected in any case. In this regard, LBG and PVA microparticles have 
similar particle size (about 1.5 µm) and density (ca. 1.40 g/cm3) and present a spherical 
shape, characteristics that are referred to enhance macrophage uptake in the context of 
passive targeting.63 Additionally, the time that microparticles remained in contact with 
macrophages was perhaps too long to permit a differentiation of affinities and this is possibly a 
variable to address in future studies. 
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TLRs recognise a variety of microbial components, including lipoproteins, peptidoglycan and 
lipoarabinomannan. Given that the LBG structure presents mannose units and is similar in a 
certain way to microbial products, TLR can initiate a signal transduction pathway for 
phagocytosis and activation upon contacting with LBG.140 This similarity can explained the 
high percentage of uptake of this polymer, comparatively with PVA.  
Comparatively with other galactomannans also tested in our laboratory, which is the case of 
partially hydrolysed guar gum (composed by M/G ratio of 2:1), LBG was still showing higher 
uptake ability in the two cell lines (data not shown). This observation indicated the expected 
preference of macrophages by mannose units in detriment of galactose. As a future study, it 
would be very interesting to activate the macrophages to an M2 state (by incubation with 
interleukin-4, for instance) and provide the exposure of macrophages to LBG microparticles 
and controls under that state. Upon infection by M. tuberculosis macrophages assume that 
activation state and express CD206,67 thus being the ideal situation to demonstrate the affinity 
of LBG microparticles.138,139 
 
4.9. Macrophage activation evaluation 
As already stated, this thesis intends to use LBG-based microparticles for production of drug 
delivery system capable of delivering antibiotics to the macrophages in a targeted strategy, by 
inducing macrophage binding and internalisation. In the last section, the high affinity of 
macrophages for these microparticles was described. When macrophages phagocytose M. 
tuberculosis, a state of activation is induced, which results in the release of several activation 
markers that lead to a final increase of the bactericidal ability of macrophages.17,100 It has been 
reported that the phagocytosis of particulates might induce the same activation state, which 
would be a great achievement for the strategy being proposed in this thesis. If an activation 
occurs, the increased release of activation markers (cytokines), such as tumour necrosis factor 
alfa (TNF-α), interleukin-1 and interleukin-8 (IL-8), which are characteristic of the M1 state, ae 
expected.17,19  
In order to evaluate this activation a polysaccharide solution and a suspension of 
microparticles of the formulation LBG.INH.RFB 10:1:0.5 (dose of 303 µg/cm2) were incubated 
with the macrophages for 24 hours. Released TNF-α and IL-8 after exposure were 
determined.  
The amount of basal release of cytokines was determined, corresponding to cells exposed 
only to CCM, which was used as control. The cells were further exposed to mannitol, a 
solution of LBG, dispersion of the microparticles and LPS. Mannitol does not have in its 
structure residues of mannose or galactose, thus serving as another control. LPS is a bacterial 
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constituent with high capacity to activate macrophages into M1 state,138 and a consistent up-
regulation of the production of TNF-α and IL-8 has been described.143  
After 24 hours of exposition to the matrix polysaccharide solution and microparticles, the 
cytokines figure 4.25) and figure 4.26 (IL-8). Matrix LBG solution and LBG-based 
microparticles demonstrated capacity to stimulate the release of both cytokines, to a level that 
was similar or superior to that elicited by LPS. As expected, mannitol solution did not present 
capacity to activate macrophages and in fact there is a reduction of the amount released in 
comparison with the basal release.   
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Figure 4.25: TNF-α released from macrophage-like THP-1 cells after exposure to LBG the form of 
solution or dispersion of microparticles.  Exposure lasted 24 hours. Results are expressed as mean 
± SEM. 
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Figure 4.26: IL-8 released from macrophage-like THP-1 after exposure to LBG the form of 
solution or dispersion of microparticles.  Exposure lasted 24 hours. Results are expressed as mean 
± SEM. 
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In both figures is observed that macrophage-differentiated THP-1 cells expressed a basal level 
of secretion of both cytokines. Differentiated THP-1 with PMA (5 ng/mL for 48 hours) 
expressed at basal level IL-8 (393 ± 25 pg/mL) and TNF-α (1952 pg/mL).144 When exposed to 
LPS the secretion increases as expected (p< 0.05), as LPS in a known activator. Other studies 
demonstrated that this molecule induces an increase of expression of TNF-α,145 thus justifying 
its use as positive control. When the cells were exposed to the LBG MPs, a significant 
increase of the expression of both cytokines (p < 0.05) was observed, which did not occur for 
mannitol-based MPs.  LBG solution significantly stimulates the production of IL-8 (p < 0.05), 
but not TNF-α (p=0.065). The obtained results indicate that LBG MPs present a similar 
capacity to induce expression of both cytockines, being able to activate macrophages.  
The literature makes available only few studies about saccharide-induced activation of 
macrophage-derived THP-1 cells. Mannose coating of drug delivery systems has been proved 
to activate macrophages (bone marrow-derived macrophages), with significant increase of 
TNF-α and another pro-inflammatory cytokines.146 Other works have been using mannose 
functionalisation for macrophage targeted drug delivery strategies.17 Galactose and di-
mannose were reported to functionalise the surface of polyanhydride nanoparticles and target 
alveolar macrophages (murine alveolar macrophages wild type and knock-down for mannose 
receptor), which showed an increase of production of pro-inflammatory cytokines, such as 
TNF-α and IL-1β.  
Results obtained in the two last sections indicated that LBG-based microparticles present a 
high percentage of uptake by macrophages and demonstrate capacity to activate 
macrophages, mediated by the production of TNF-α and IL-8, indicating the potential of these 
microparticles for macrophage targeting and activation strategies.  
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5. Conclusion 
Microparticle-based carriers hold a considerable potential for the delivery of antibiotic drugs in 
infectious respiratory diseases. The administration of drug carriers directly to the lung, by 
means of inhalation, might be an effective therapeutic approach. In this context, this thesis 
proposed the development of a dry powder formulation composed of locust bean gum (LBG) 
and produced by spray-drying. Considering the structural composition of LBG, the polymer 
was deemed adequate to design a delivery strategy targeted to the alveolar macrophages, as 
a strategy in tuberculosis therapy. 
Locust bean gum microparticles were successfully produced by spray-drying although a 
content of HCl is needed to reduce the viscosity of the spraying dispersion. Despite the 
differences of solubility of Isoniazid and Rifabutin, the two model antibiotics selected, both 
were successfully incorporated in LBG microparticles, with association efficiencies above 82%. 
The aerodynamic properties of microparticles suggest their suitability for the objective of deep 
lung delivery in the ambit of tuberculosis therapy. These presented an aerodynamic diameter 
between 1.27 to 1.90 µm, Feret’s diameter of 1.26 - 1.50 µm and a pollen-shaped shape. 
These characteristics were considered at least theoretically to render the ability to reach the 
alveolar zone where macrophages hosting mycobacteria are located.  
The analysis by XRD showed an absence of crystalline profile of the microparticles as is 
characteristic of formulations obtained by spray-drying.  
The release assays determined a rapid release of INH from microparticles LBG.INH, which 
was a little slower when both drugs were associated in the same formulation. In that case, 
RFB release was also more prolonged and similar to INH release, with 70-80% of drugs being 
released in 60 minutes. The cytotoxic behaviour of microparticles was characterized in two cell 
lines representative of the alveolar zone (A549 cells for alveolar epithelium and THP1 cells for 
macrophages). The general conclusion was that RFB imposes a certain degree of toxicity in 
both cell lines, especially for prolonged exposition (24 hours). INH in turn, does not exhibit any 
cytotoxic effect. It was also indicated that RFB toxicity is potentiated by the association of RFB 
to HCl. In this perspective, a lower amount of RFB is suggested to be encapsulated and 
possibly another excipient to reduce LBG viscosity. Another alternative could be the 
substitution of RFB by another drug such as pyrazinamide or a new-drug (for example, PA-
824). Formulations presented as aerosol elicited higher level of toxicity but it is suggested that 
tested doses are still very high comparing with the in vivo conditions. A clear dose-dependent 
effect was anyway demonstrated. 
It was demonstrated that macrophages have high affinity for LBG microparticles in two cell 
lines, human macrophage-like THP-1 cells and rat alveolar macrophages (NR8383).  The 
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exposure to LBG microparticles was also shown to activate macrophages. These results as a 
whole demonstrate the potential of LBG to be used as matrix material in microparticles aimed 
at an application as inhalable antibiotic carriers in the ambit of lung tuberculosis therapy. 
These formulations presented the advantage of producing microparticles with mannose, 
without an extra-step, to attach ligands. The composition of these carrier can be properly 
designed to have a composition that favours both the interaction with these cells, mediated a 
specific recognition, and the consequent internalisation, which will ensure the localisation of 
drugs inside the infected niche. And a capacity of activation macrophage, benefits an improve 
in inflammatory response 
This strategy would accumulate the drugs in the primary site of infection, possibly increasing 
the drug therapeutic effect and decreasing the side effects. As a whole, this would definitely 
lead to increased patient compliance and to the successful treatment of some concerning 
diseases associated with macrophage parasites. 
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Table 1: Caracterisation of Isoniazid and Rifabutin. Adapted from reference 10, 23, 70,147. 
10,23,70,147 
Characterisation Isoniazid Rifabutin 
Indication  
Antibacterial agent used primarily 
as a tuberculostatic. First-line 
agent.  
A broad-spectrum antibiotic that is 
being used as prophylaxis against 
disseminated Mycobacterium avium 
complex infection in HIV-positive 
patients. 
Pharmacodynamics 
Isoniazid is a bactericidal agent 
active against some organisms of 
the genus Mycobacterium. It is a 
highly specific agent, ineffective 
against other microorganisms. 
Isoniazid is bactericidal to rapidly-
dividing mycobacteria, but is 
bacteriostatic if the mycobacterium 
is slow-growing. 
Rifabutin is an antibiotic that inhibits 
DNA-dependent RNA polymerase 
activity in susceptible cells. 
Specifically, it interacts with 
bacterial RNA polymerase but does 
not inhibit the mammalian enzyme. 
It is bactericidal and has a very 
broad spectrum of activity against 
most gram-positive and gram-
negative organisms (including 
Pseudomonas aeruginosa) and 
specifically Mycobacterium 
tuberculosis. Because of rapid 
emergence of resistant bacteria, 
use is restricted to treatment of 
mycobacterial infections and a few 
other indications.  
Mechanism of action 
A  pro-drug  activated  by  catalase  
peroxidase, the drug inhibit  of  
synthesis  of  mycolic  acids,  
through formation  of  a  covalent  
complex  with  an  acyl  carrier  
protein  and α-ketoacyl  carrier  
protein  synthetase. 
Rifabutin acts via the inhibition of 
DNA-dependent RNA polymerase 
in gram-positive and some gram-
negative bacteria, leading to a 
suppression of RNA synthesis and 
cell death. 
Minimum Inhibitory 
Concentration for 
Mycobacterium 
tuberculosis (µg/mL) 
0.01 – 0.2 0.125 
Chemical formula C6H7N3O C46H62N4O11 
Mass molecular 
(g/mol) 
137.14 847.01 
Structure 
  
Melting point (ºC) 171.4 °C Not be determined 
Water Solubility 1.4 E+ 005 mg/L (at 25 °C) Minimally soluble (0.19 mg/mL) 
Partition-coefficient 
(logP) 
-0.70 4.1 
   
 
